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Resumo 
 
Células mesenquimais do estroma, lipidómica, resposta imune, doenças 
auto-imunes, doenças inflamatórias, espectometria de masssa. 
 
As células mesenquimais do estroma são células estaminais adultas que 
apresentam propriedades imunossupressoras e têm sido aplicadas como 
terapia clínica em vários estudos clínicos relativos a doenças 
autoimunes. Apesar do vasto número de estudos clínicos que utilizam 
estas células, ainda não se conhece o mecanismo de ação das mesmas, 
nem foram ainda identificados marcadores permitam avaliar o seu 
potencial imunomodulador. A lipidómica poderá dar algumas respostas a 
estas questões uma vez que os lípidos são importantes componentes das 
células, desempenhando um papel na sinalização celular. No presente 
trabalho estudou-se o lipidoma das células mesenquimais e avaliou-se a 
sua variação consoante o meio de cultura e a presença de estímulos pró-
inflamatórios, mimetizando as condições fisiológicas em que as células 
são utilizadas. Este foi o primeiro estudo que analisou as diferenças no 
perfil fosfolípidico entre células mesenquimais do estroma e avaliou a 
variação do lipidoma destas células após a  sua estimulação por 
mediadores pró-inflamatórios. Este estudo foi conduzido num primeiro 
conjunto de células cultivado num meio padrão suplementado com soro 
animal e num segundo conjunto de células cultivado num meio sintético. 
Nas células cultivadas no meio padrão, observou-se uma diminuição nas 
espécies moleculares de fosfatidilcolina (PC) com cadeias de ácidos 
gordos (FAs) após estímulos pro-inflamatórios. A quantidade de 
PC(40:6) também diminuiu, relacionando-se com o aumento expressão 
de lisoPC (LPC)(18:0) – LPC anti-inflamatória – em células estimuladas. 
Simultaneamente, a quantidade relativa de PC(36:1) e PC(38:4) 
aumentou. TNF-α and IFN-γ também levou ao aumento dos níveis de 
fosfatidiletanolamina PE(40:6) e diminuiu os níveis de PE(38:6). 
Também se verificou um aumento da expressão de fosfatidilserina 
PS(36:1) e esfingomielina (SM)(34:0), bem como a diminuição na 
expressão de PS(38:6). Contudo, em células mesenquimais cultivadas 
em meio sintético, com TNF-α and IFN-γ apenas aumentaram os níveis 
de PS(36:1). Estes resultados indicam que o metabolismo dos lípidos é 
modulado durante a ação imunossupressora das células. 
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Mesenchymal stromal cells are adult stem cells found mostly in the bone 
marrow. They have immunosuppressive properties and they have been 
successfully applied as biological therapy in several clinical trials 
regarding autoimmune diseases. Despite the great number of clinical 
trials, MSCs’ action is not fully understand and there are no identified 
markers that correlate themselves with the immunomodulatory power. A 
lipidomic approach can solve some of these problems once lipids are one 
of the major cells’ components. Therefore, in this study cells’ lipidome 
was analysed and its deviations were evaluated according to the medium 
of culture and to the presence of pro-inflammatory stimuli, mimicking 
physiological conditions in which these cells are used. This was the first 
study ever made that aimed to analyse the differences in the 
phospholipid profile between mesenchymal stromal cells non-stimulated 
and stimulated with proinflammatory stimulus. This analysis was 
conducted in both cells cultured in medium supplemented with animal 
serum and in cells cultured in a synthetic medium. In cells cultured in the 
standard medium the levels of phosphatidylcholine (PC) species with 
shorter fatty acids (FAs) acyl chains decreased under pro-inflammatory 
stimuli. The level of PC(40:6) also decreased, which may be correlated 
with enhanced levels of lysoPC (LPC)(18:0) - an anti-inflammatory LPC 
- observed in cells subjected to TNF-α and IFN-γ. Simultaneously, the 
relative amounts of PC(36:1) and PC(38:4) increased. TNF-α and IFN-
γ also enhanced the levels of phosphatidylethanolamine PE(40:6) and 
decreased the levels of PE(38:6).  Higher expression of 
phosphatidylserine PS(36:1) and sphingomyelin SM(34:0) along with a 
decrease in PS(38:6) levels were observed. However, in cells cultured in 
a synthetic medium, TNF-α and IFN-γ only enhanced the levels of 
PS(36:1). These results indicate that lipid metabolism and signaling is 
modulated during mesenchymal stromal cells action. 
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I. INTRODUCTION 
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Introduction 
1. Mesenchymal Stromal Cells 
 In the last years, mesenchymal stromal cells (MSCs) have been successfully 
applied in many clinical trials (1). MSCs are primitive cells with origin in the 
mesodermal germ layer. They are considered adult stem cells, once these cells are 
characterized as capable of self-renewal and directed differentiation. In fact, they are 
able to originate connective tissues, skeletal muscle cells and vascular system cells 
(1). 
 MSCs show some characteristics, namely ease of accessibility for isolation, 
enormous expansion potential in culture without losing the ability to differentiate, 
presumptive plasticity, immunosuppressive properties, use in allogeneic 
transplantation, paracrine-mediated effects, homing and migratory behaviour to sites 
of tissue injury that support their use as a biologic therapeutic for several clinical 
applications (1) (Figure 1). All this topics will be addressed further in this work. 
 
 
Figure 1. Schematic representation of several current applications of mesenchymal stem cells 
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1.1 Location and differentiation of MSCs 
Adult stem cells can be found in different adult tissues, such as brain, heart, 
lungs, kidneys and spleen but display different characteristics depending on the 
source. However, adult stem cells from bone marrow (BM) are the best characterized 
ones (1). In BM it is possible to find a wide diversity of cells, including hematopoietic 
stem cells, macrophages, erythrocytes, fibroblasts, adipocytes and endothelial cells. In 
the heterogeneous cell population found in BM, there is a particular subset of 
nonhematopoietic stem cells with the ability to differentiate in cells from different 
lineages.  These cells are MSCs. MSCs are not capable to produce blood cells because 
they are not hematopoietic stem cells. Therefore MSCs are classified as 
nonhematopoietic, multipotential stem cells capable of originating both mesenchymal 
and nonmesenchymal cell lineages (1–3).  
Ernest A. McCulloch and James E. Till were the first to discover MSCs in the 
1960s and named them as clonal bone marrow stromal cells (3). Later in the 1970s 
Friedenstein and his research group performed further studies and characterized these 
cells as fibroblast-like that can be obtained from bone marrow due to their intrinsic 
plasticity in culture. He distinguished these cells as multipotential stromal precursor 
cells, spindle-shaped and clonogenic in culture, naming the stromal cells colony-
forming unit fibroblasts (CFU-F) (Figure 2) (4,5). 
  
 
Figure 2. MSCs developed in culture. Appearence of MSCs after second passage under inverted 
microscope (100x) (adapted from (6)). 
 
These cells were capable of making bone in subcutaneous transplants. 
Furthermore, Friedenstein was able to prove the CFU-F’s self-renewal potential 
because he demonstrated MSCs were able to regenerate heterotopic bone tissue in 
several transplants. Several research groups have then focused their work in 
expanding these findings and came across with results that revealed CFU-F’s capacity 
 5 
to differentiate into a variety of mesenchymal lineages’ cells such as osteoblasts, 
chondrocytes, adipocytes and myoblasts both in vitro and in vivo (7–11). Apart from 
this discovery, it became obvious the possibility to use these cells in clinical 
applications and they have been applied as cellular sources to regenerate bone, 
cartilage and adipose tissues (2). Later in 2007 these cells were renamed 
“mesenchymal stromal cells” or MSCs by Caplan and colleagues (8). Further studies 
reported MSCs as capable of originating cardiomyocytes, neurons and astrocytes in 
vitro and in vivo (1). However, MSCs power of differentiation depends on the age of 
MSCs donors (12). 
Nevertheless scientific community is not sure about MSCs’ true nature and 
identity, comprising location, origin and multipotential capacity. MSCs can be 
obtained from several different tissues, including adipose tissue, liver, muscle, 
amniotic fluid, placenta, umbilical cord blood and dental pulp, however the main 
source is BM (1,3,12). Although, only between approximately 0,01 and 0,001% of 
BM aspirates are MSCs. Even though this very low percentage, there is great interest 
in these cells once they have a great expansion rate in culture and they can also be 
easily isolated from small aspirates that are also easily obtained (1). 
 
1.2 Culture and Expansion of MSCs 
In order to clinically apply MSCs, it is necessary to have a great amount of 
cells. So it becomes necessary to expand these cells ex vivo. Despite stem cells huge 
ability to continuously regenerate and expand in vivo, they have limited proliferation 
rate in ex vivo settings. Moreover, MSCs from the same donor can have different 
capability to expand. There are several parameters that influence MSCs’ expand rate. 
Culture conditions are within these parameters. In fact, nutritional level, cell 
confluence, oxygen level, number of passages and plastic surface quality interfere 
with MSCs growth (13). Cell-seeding density and media used for cell propagation 
also change MSCs functional properties. The most common media used to culture 
MSCs is Dulbecco’s modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (FBS). However, the use of a serum from animal origin gathers several 
concerns regarding variability and immunological reactions originated by reactions 
between bovine sialic acid and protein derivatives in MSCs. For this reason, xeno-free 
serum is a really positive alternative for culturing cells. 
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MSCs can also be developed in serum-free media (SFM) becoming possible to 
simultaneously overcome the regulatory requirements of these cells and improve the 
efficiency of production systems. SFM also selectively isolate MSCs and enrich their 
characteristics. Data gathered also demonstrated MSCs culture in synthetic media 
have powerful immunomodulatory abilities.  
According to the media or condition in which MSCs are cultured, they present 
different characteristics and properties. However, few studies have characterized 
MSCs grown in SFM. Properly characterize cells cultured in this media will allow a 
wider use of MSCs cultured in SFM and, consequently, concerns regarding bovine 
serum will be avoided. 
    
1.3 Growth and Phenotypic characteristics of MSCs 
According to kinetic studies previous conducted, MSCs growth has 3 different 
phases, namely (1) initial lag phase lasting 3 to 5 days, (2) fast expansion and (3) 
stationary phase. In the end of the lag phase, cells begin to secrete dickkopf-1 (Dkk-1) 
that inhibits the Wnt signalling cascade. As consequence, the levels of β-catenin drop 
and cell proliferation stops. At the same time, epidermal growth factor receptor-1 
(HER-1) interacts with heparin-binding epidermal growth factor (HB-EGF), inducing 
MSCs proliferation and inhibiting differentiation (13).  
MSCs do not have a unique specific cell surface marker and if they are 
obtained from different sources they show different proliferative and multilineage 
potential. To clarify how to identify MSCs, the International Society for Cellular 
Therapy has established minimum criteria (14): 
1) plastic-adherent under standard culture conditions; 
2) positive expression of cluster of differentiation (CD) 105, CD73 and CD90, 
plus absent expression of hematopoietic cell surface markers CD34, CD45, 
CD11a, CD19 and human leukocyte antigen-D related (HLA-DR); 
3) under specific stimulus, cells should differentiate into osteocytes, adipocytes 
and chondrocytes in vitro; 
 
However, many other markers can be analysed (absence or presence) in order to 
characterize MSCs. Among the huge diversity of markers, it is possible to find 
proteins with different functions, such as cellular adhesion molecules, integrins, 
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selectins, chemokine receptors or membrane-bound receptors involved in apoptosis or 
necrosis. The markers analysed are proteins naturally expressed by several different 
cells, namely stem cell precursor cells, endothelial or epithelial cells, T-lymphocytes, 
B-lymphocytes, natural killer (NK) cells, macrophages/monocytes, granulocytes, 
dendritic cells (DCs), platelets and erythrocytes. MSCs surface marker expression 
profiles can vary depending on their source, isolation procedure, in vitro senescence 
and detections methods (15). 
Finding unique markers to identify and characterize MSCs is particularly 
important, once this information will allow to obtain and to expand more 
homogeneous MSCs populations. Furthermore, it will allow developing therapeutic 
MSCs for a specific disease indication with improved disease-specific efficiency. 
However, despite some of this information remains unknown, MSCs have already 
been successfully applied in many pathologies. 
 
2. Animal and Clinical Application of MSCs 
 MSCs have the ability to repair or regenerate damaged tissues and thus can be 
used to treat some human diseases. MSCs can be isolated and expanded from 
different sources and their use to tissue engineering and cell therapy has been 
exploited (15). As a matter of fact, the initial therapeutic interest in MSCs was based 
in their ability to differentiate into several multilineages and in applying this ability to 
regenerate tissues and organs. MSCs have already been applied in bone and cartilage 
repair. For example, MSCs were successfully used to improve bone healing (16) and 
in osteogenesis imperfect (17,18). Also in bone reconstruction (19) and in vascular 
wall restoration (20) have MSCs revealed reliable. 
Nevertheless, MSCs possess other characteristics that have drawn the interest 
of researchers. In fact, as referred above, MSCs interfere with immune cells and 
inhibit the proliferation of activated allogeneic lymphocytes either in vitro as in vivo, 
crossing histocompability barriers. Moreover, MSCs home towards damaged tissue 
through several growth factors, cytokines and chemokines, enhancing the efficiency 
of their repair and immunomodulatory mechanisms (15). MSCs also act upon most 
major components of the innate and adaptive immune system and they show 
proangiogenic, cytoprotective and antifibrotic effects. In addition, MSCs have proven 
capable of migrating towards tissues experiencing inflammatory events and they are 
“licensed” by inflammatory cytokines and pattern recognition receptor (PRR) ligands 
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to become more powerful (21). For these reasons, most recently there has been a 
rising interest in applying these cells as a treatment for inflammatory and autoimmune 
diseases (21). Up to date, a total of 432 studies are registered in the ClinicalTrial.gov 
database. Some of these studies focus in therapeutically applying MSCs as 
modulatory mediators in models of inflammatory and autoimmune diseases, such as 
Graft versus Host Disease (GvHD), multiple sclerosis and Crohn’s disease (CD). 
Some of the performed studies and their results are briefly addressed below.   
 
2.1 MSCs application in Graft versus Host Disease 
 GvHD is among the pathologies in which MSCs immunomodulatory 
characteristics are more often therapeutically applied. GvHD is a mortal complication 
characterized by donor’s T cells aggression to host’s tissue. Steroids are the most 
common form of treatment, however some patients are refractory and no effective 
therapy exists. Back in 2004, Le Blanc successfully infused haplo-identical MSCs in a 
patient suffering from grade IV acute GvHD. The patient received two infusions of 
MSCs and no toxicity events were detected. Upon the second infusion, the patient 
showed a complete response and no minimal residual disease was found either in 
blood or in BM (22). In further phase II clinical trials, haplo-identical MSCs were 
infused in 18 patients, while 79 patients received MSCs from third-party HLA-
mismatched donors. Surprisingly, 30 patients responded completely and 9 showed 
some improvements. Once again, no patient developed any kind of adverse effects  
(23).  
 In another phase II clinical trial (24), allogeneic MSCs were infused in 31 
patients suffering from acute GvHD. Of the treated patients, none developed toxic 
events and 94% developed an initial response, 77% responded fully and 17% showed 
a partial response. In a larger phase III clinical trial, from 260 steroid-resistant GvHD 
patients, interesting results were obtained. In this study, patients with GvHD present 
in the liver and in the gastrointestinal tract showed the best improvement after being 
infused with allogeneic MSCs, indicating some tissues experiencing GvHD are more 
susceptible to MSCs action than others (25).      
 
2.2 MSCs application in Multiple Sclerosis 
 MSCs application is of interest also in patients suffering from multiple 
sclerosis. Multiple sclerosis is a chronic autoimmune inflammatory disease in which 
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nerve cells from the brain and spinal cord suffer demyelination. In a pilot clinical 
study, 5 patients with advanced multiple sclerosis showed great improvements after 
administration of ex vivo-expanded autologous MSCs. This trial was very important 
to prove MSCs safety and feasibility as a therapy for patients with multiple sclerosis 
(26). In another phase II study concerning 15 patients, the previous results were 
confirmed.  Moreover, more regulatory T cells were found, along with weaker 
proliferative responses of lymphocytes and activation markers from DCs (27). In 
general, MSCs decline the progression of general disability in patients suffering from 
multiple sclerosis (28). 
Studies conducted in experimental autoimmune encephalomyelitis (EAE) 
model of multiple sclerosis, in which rats were injected with MSCs, showed MSCs 
transplantation weakened the clinical severity of EAE, along with central nervous 
system (CNS) inflammation and demyelination. It is supposed this happens because 
MSCs engraft in lymphoid organs where they induce T-cell aenergy (29). Another 
studied proved MSCs are capable of supressing proteolipid protein (PLP)-induced 
EAE when administrated by iv in rats (30). 
 
2.3 MSCs application in Crohn’s Disease  
CD is a pathology whose origin is still not clear. CD can affect the entire 
gastrointestinal system with continuous transmural inflammation and fistulization. 
Not many studies using MSCs as a biological therapy have been performed. However, 
the results obtained from these studies were very promising. As a matter of fact, in a 
phase I clinical trial, 6 out of 8 patients suffering from CD and locally injected with 
MSCs showed healed fistulas after the injection and no controversial effects were 
registered. This results were proved in the subsequent phase II trial (31).  
Further and more extensive applications of MSCs in other inflammatory and 
autoimmune diseases require a deeper knowledge about MSCs’ behaviour, 
phenotypic characteristics and mechanisms. Lipidomics approach can provide some 
of the needed information. 
 
3. The main targets of MSCs’ immunomodulatory effects 
 MSCs could be successfully applied in all the previous pathologies due to 
their effects upon the immune system (IS) and its cells. IS is the system used to 
protect the host from pathogens and it distinguishes different pathogens, acting 
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accordingly in a process known as immune response. Monocytes, DCs, T and B cells 
are some of the cells responsible for the referred immune response (32).  
 IS can be subdivided in two systems dependent of each other: innate and 
adaptive immune systems. The innate immune system acts upon pathogens that break 
physical barriers like the skin. Leucocytes have PRRs that identify and bind to 
pathogen-associated molecular patterns from the pathogen, inducing pathogen 
apoptosis or recruiting inflammatory mediators (32). 
The adaptive immune system uses antibodies and T and B cells that act upon 
specific pathogens. This originates memory of the pathogens and consequently 
promotes a faster response from IS the next time T and B cells are exposed to the 
pathogen (32). 
In both immune systems, IS triggers inflammatory pathways evolving a 
complex process network composed by inflammatory cells and mediators. Once these 
cells and mediators are activated, they initiate and later stop inflammation acute 
phase. This process occurs only at the infected tissue, resulting in angiogenesis and 
renewed tissue. It is possible to distinguish two types of inflammatory mediators: 
mediators of cell adhesion and chemotactic mediators. Intercellular Adhesion 
Molecule (ICAM-1) also known as Cluster of Differentiation 54 (CD54) and Vascular 
Adhesion Molecule 1 (VCAM-1) also known as Cluster of Differentiation 106 
(CD106) are mediators of cell adhesion and they are involved in the leucocytes 
interactions, as well as in the interaction between leucocytes and endothelial or target 
cells. Among chemotactic mediators are cytokines, interleukins, chemokines and 
bioactive lipids that are responsible for leucocytes chemotactic migration and are 
involved in angiogenesis, collagen production and proliferation of hematopoietic 
precursors (32). 
 
3.1 Dendritic cells 
 DCs are the main antigen presenting cells (APCs) and they are specialized in 
uptaking, transporting and presenting antigens (Ags). These cells also stimulate naïve 
and memory T cells and interact with B cells and NK cells (33). 
 Immature DCs (iDCs) are found in peripheral tissues, where they capture and 
process Ags. However, iDCs do not have the capacity to stimulate T cells. Locally 
produced inflammatory cytokines are responsible for DCs maturation, in a process 
characterized by upregulation of MHC and costimulatory molecules, production of 
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interleukine (IL)-12 and migration towards lymphoid tissue (33,34). Therefore, 
mature DCs (mDCs) show lower capacity to uptake Ags, but acquire the ability to 
stimulate T cells (34). In fact, only mDCs are capable of inducing immunogenic T 
cell responses without inducing tolerance (33,34). 
 
3.2 T cells 
 T cells, also known as T lymphocytes, are a type of lymphocyte characterized 
by the presence of a T cell receptor (TCR) on its cell surface.  T cells function is to 
destroy pathogens and viruses that replicate themselves inside cells and, consequently 
are not recognized by antibodies present in the blood or in extracellular spaces (35). 
 T lymphocytes need to interact directly with the cells bearing the antigen they 
recognize, in order trigger an immune response. Cytotoxic T cells are the ones that act 
more directly. Infected cells display in their surface antigens derived from the 
pathogen. These antigens are recognized by cytotoxic T cells that act accordingly and 
kill the infected cells. Usually, cytotoxic T cells display CD8 on their surfaces (35). 
 Other T lymphocytes display in their surfaces CD4 marker and are called 
helper T, or TH cells. However, CD4 T cells can be divided into two subsets with 
different roles in defending the body. The first subset of CD4 T cells - TH1 cells - 
controls intracellular bacterial infections, activating macrophages and inducing other 
phagocytic antibacterial mechanisms. TH1 cells also release cytokines and 
chemokines that direct macrophages towards the inflammation site (35). 
 T cells are also important in killing extracellular pathogens by activating B 
cells. This function is up to the second subset of CD4 T cells - TH2 cells. Only a 
limited number of antigens are capable of directly activating B cells. Most of them 
require TH2 cells to stimulate B lymphocytes proliferation and differentiation into 
antibody secreting cells (35).  
   
3.3 B cells 
 B cells, often called B lymphocytes, are responsible for producing antibodies, 
present pathogens and release cytokines. These cells flow in the bloodstream, where 
they recognized pathogens relying upon their antigen specific receptors: membrane-
type surface immunoglobulins (36). 
 When B cells get across with pathogens flowing in the bloodstream, they 
capture the foreign body and are activated through B cell receptor pathways. As a 
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result, the expression of MHC class II antigens and co-stimulatory signals, as for 
example CD80/86 molecules, is upregulated. Subsequently, the stimulated B cells go 
to the spleen and expose T cells to pathogen’ specific antigens, greatly activating 
CD4+ T cells (36). 
 B cells can also be involved in aggravating autoimmunity and controlling 
infection propagation. When healthy cell are injured, they release autoantigens that 
are captured by autoreactive B cells. Once again, B cells present the autoantigens to 
autoreactive T cells from the spleen, enhancing specific T-cell mediated 
autoimmunity. As a result, pathogenic T cells receptors spread and B cells secret 
greater amounts of antibodies. B cells can also produce pathogenic cytokines, 
enhancing autoreactive T cells proliferation and activation and leading to T cell 
mediated autoreactivity. All together, this leads to more deterioration of target cells. 
All this together forms a vicious cycle of amplified autoreactivity and target damaged 
cells ate the site of autoimmunity (36).   
 
3.4 Natural Killer cells 
 NK cells are important effector cells of innate immune system and migrate 
towards peripheral tissues driven by chemokines and type I interferones (IFNs) upon 
inflammation. NK cells express at their surface receptors specific for the chemokines 
usually secreted during inflammatory events by macrophages, neutrophils, DCs and 
endothelial cells (37).   
NK cells also display intense cytotolic activity against cells infected by a virus 
or a tumour. NK cells show several surface receptors involved whether in inhibitory 
and activation pathways. The main inhibitory receptors are killer immunoglobulin-
like receptors (KIRs) that bind specifically MHC class I molecules. Under normal 
condition, autologous cell express these molecules, preventing NK cells activation. 
However, tumour- or virus-infected cells downregulate the expression of MHC class I 
molecules at the cell surface, resulting in few inhibitory interactions and consequently 
in activation of NK cells. Once NK cells are activated, infected cells become 
susceptible to killing mediated by NK cells (37,38). 
However, iDCs are very susceptible to NK cells-mediated lysis, despite 
expressing MHC class I molecules. It is supposed this mechanism serves to control 
the quality of DCs undergoing maturation. NK cells also eliminate DCs that would 
not efficiently present Ags and prime T cells (37).  
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4. Immunomodulatory effects of MSCs 
 As previous referred, MSCs have the ability to modulate immune responses. 
In fact, MSCs can supress secondary alloimmune responses in vitro and primary 
alloimmune responses (39). MSCs also manage to induce lymphocyte proliferation 
whether they are autologous or allogeneic to the tissue, indicating MSCs exert their 
immunomodulatory effects independently of MHC (40). Nevertheless, MSCs act 
upon most cells of the immune system, namely T and B cells, DCs and NK cells 
(Figure 3). 
 
 
Figure 3. Immunomodulatory effects of MSCs over immune system’s cells. Schematic and 
simplified representation of MSCs effects over NK cells, DCs, T and B cells. 
   
 
4.1 Immunomodulatory Effects of MSCs on DCs 
The induction of immune response depends on both T cells and interactions 
between DCs and T cells. MSCs modulate the expression and antigen-presentation 
capacity of DCs before lymphocyte activation and proliferation. Jiang and colleagues 
performed one of the earliest studies ever regarding MSCs immunomodulation over 
DCs. Jiang demonstrated monocytes cultured with MSCs fail to express either 
immature as mature DCs markers, i.e., in the presence of MSCs monocytes do not 
differentiate into DCs (41). More specifically, MSCs stop DCs generation by 
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inhibiting precursor cells (CD34+ and monocytes) differentiation into DCs (33). 
MSCs mediate their effect on DCs differentiation mainly through prostaglandin 2 
(PGE2) (supresses T cells receptor signalling) during the early stages, i.e. during 
cytokine-induced monocytes differentiation into iDCs (42). However, primed MSCs 
also secrete IL-6 and vascular endothelial growth factor (VEGF). VEGF is involved 
in MSCs immunosuppressive effect and IL-6 is an important cytokine involved in the 
immune regulatory mechanism employed by MSCs. Furthermore, IL-6 impairs 
monocytes differentiation into DCs when monocytes are cultured with MSCs (43). 
However, other studies stated MSCs and DCs interact directly with each other during 
DCs activation using adherent junctions (44).  
Later studies concerning MSCs-DCs’ phenotype found results slightly 
different from the ones obtained by Jiang. In fact, MSCs-DCs display mature DCs 
(maDCs) phenotype and normal IL-12 (T cells stimulating factor) and IL-10 (anti-
inflammatory cytokine) production, although they also maintain some characteristics 
of iDCs, namely their structure resembling a podosome and endocytic activity and not 
being capable to form active immune synapses with lymphocytes. MSCs alter DCs 
function by interfering with DCs activation through an alteration of the cytoskeleton 
organization in a long-lasting effect (44). As a result, DCs become regulatory DCs 
capable of both inhibiting alloreactivity of T cells and inducing the generation of 
alloantigen-specific regulatory T cells in a manner independent of IL-10 secretion 
(45). 
MSCs also interfere directly with iDCs and mDCs. When MSCs act upon 
iDCs, these either convert to monocytes or do not enter maturation, failing to induce 
T cells activation (33,41). IL-12 production is detrimental to DCs maturation and 
function but in the presence of MSCs, IL-12 production is greatly reduced (41). MSCs 
induce mDCs proliferation and differentiation into a different DC population - 
regulator DCs (regDCs) population - and LPS stimulation is not capable of reversing 
this trend. This novel regDCs population supress T cells (46). 
 Although several studies have reported MSCs effect in DCs maturation, only 
in 2013 one mechanism was proposed regarding how this process is controlled. MSCs 
or DCs in monoculture release low amounts of IL-10. IL-10 is released in 
considerable amounts by monocyte-derived iDCs and by stimulated mDCs; it is 
known IL-10 inhibits DCs differentiation and function. However, when MSCs and 
DCs are co-cultured IL-10 combines itself with IL-10 receptor, activating JAK-STAT 
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signal transduction pathway. JAK-STAT signalling pathway transmits chemical 
information from outside the cell into gene promoters on the DNA, leading to DNA 
transcription. When MSCs and DCs are co-cultured, this pathway is activated and IL-
12 secretion is inhibited, leading to impaired maturation of DCs, increased number of 
iDCs and decreased number of mDCs (47).  
 
4.2 Immunomodulatory effects of MSCs on T cells 
MSCs have a rather unique immunophenotype profile characterized by low 
expression of costimulatory molecules and absence of human leukocyte antigen 
(HLA). This profile provides MSCs the ability to actively modulate T-cell 
proliferation. Di Nicola and colleagues were able to prove that T cell proliferation 
stimulated by allogeneic peripheral blood lymphocytes (PBL) and DCs or mitogen as 
phytohemagglutinin (PHA) or IL-2 is inhibited by MSCs in a dose dependent manner 
(48). Interestingly, this effect still occurs when MSCs’ source is different from both 
the T cells and the stimulators molecules source (49). Probably because MSCs do not 
express MHC class I and II molecules (50). Cytokines released by MSCs, such as 
recombinant human hepatocyte growth factor (rhHGF) and/or recombinant human 
hepatocyte growth factor β1 (rhTGF-β1) mediate the inhibitory effects. Finally, Di 
Nicola and colleagues have also demonstrated T lymphocytes inhibited by MSCs do 
not enter apoptosis; in fact, when restimulated with cellular or humoral activators if 
MSCs are not present, these cells are still able to proliferate (48,49). However, MSCs 
need to be induced in order to act as an immunoregulator and this process is called 
“priming”. Once MSCs are primed by proinflammatory cytokines, they perform all 
the effects referred above and also decrease IFN-γ (macrophages activator) and IL-2 
secretion by activated T cells (49). However these cells exert their immunoregulatory 
activity in culture and in contact with T-cells, i.e., MSCs mediate their 
immunoregulatory activity in a cell-contact dependent manner (51). 
Interestingly, despite MSCs specifically but reversibly inhibit T cells proliferation, 
they do not completely supress T cells activation. In fact, MSCs stop cell division at 
G0/G1 phase of the cell cycle inhibiting T-cell proliferation, but T cells’ surface 
continues to show activators molecules. MSCs are able to stop the cell cycle because 
they block cyclin D2 induction. Cyclin D2 induction is important for cell cycle G1/S 
transition. Also MSCs inhibit T-cell effector function because the number of IFN-γ 
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producing cells are reduced in T cells cultured with MSCs (52,53). T cells co-cultured 
with MSCs secrete no cytokines besides IFN-γ and tumor necrosis factor α (TNF-α). 
TNF-α stimulates acute phase reaction in response to inflammation. IFN-γ induces 
the expression of the protein B7-H1 on MSCs, triggering MSCs’ immunosuppressive 
effects (54). It is important to refer that B7-H1 induces T cell proliferation and IL-10 
secretion. IFN-γ in addition with other cytokines, such as TNF-α, IL-1α or IL-1βs 
(proinflammatory cytokines) can also be used to prime MSCs. TNF-α and IL-1α 
induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
pathway. This pathway induces some cell responses to several stimuli, such as 
cytokines and it also regulates immune response to infection. NF-κB activation by 
TNF-α leads to the activation of MSCs regulatory function. According to Dorronsoro, 
once TCR is stimulated, T cells begin to clonal expanding and to secrete cytokines, 
such as TNF-α. TNF-α stimulates NF-κB pathway, via tumor necrosis factor receptor 
1 (TNFR1), in MSCs present in inflammatory environment, triggering MSCs 
immunosuppression (55). NF-κB pathway is also activated by the ligation between 
toll-like receptors (TLRs) 3 and 4 present in MSCs and their respective ligands. TLRs 
are widely distributed on immune system’s cells and their activation is essential for 
inducing immune response and enhancing adaptive immunity against pathogens (56).  
In APCs expressing indoleamine 2,3-dioxygenase (IDO) is a very important 
effector pathway that immunosuppresses T-cell responses to autoantigens and fetal 
alloantigens in vivo. This pathway is induced by IFN-γ and other proinflammatory 
cytokines; IDO catalyzes tryptophan conversion into kynurenine. Despite MSCs do 
not intrinsically express IDO, IFN-γ induces the production of considerable amounts 
of IDO by primed MSCs in a dose-dependent manner. Tryptophan depletion by IDO 
is a T-cell inhibitory effector mechanism employed by MSCs (57). 
Nitric oxide (NO) is known to inhibit T cell proliferation and it was reported 
MSCs produce NO when they differentiate into chondrocytes. Furthermore, NO 
mediates T-cell suppression by MSCs and also acts inhibiting Stat5 phosphorylation 
(Stat5 is required for T cell division) (58). 
Curiously, MSCs immunomodulation does not act only upon T cell proliferation 
and activation. According to a study conducted by Rasmusson, MSCs loaded with 
MHC class I peptide epitopes are resistant to lysis by cytotoxic T lymphocytes 
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(CTLs) and the interaction between MSCs and CTLs does not induce the production 
of proinflammatory cytokines by CTL (59). 
A new subset of TH cells was discovered and denominated TH17. TH17 cells, a 
population of CD4+ cells, play an important role protecting the host against 
extracellular pathogens and in murine models of inflammatory disease. MSCs affect 
TH17 lineage differentiation and inhibit the production of proinflammatory cytokines, 
while simultaneously increase the production of IL-10 and the expression of forkhead 
box P3 (FOXP3). FOXP3 is one of the main regulators of regulatory T cells (Tregs) 
development and function. MSCs induces TH17 cells to develop a phenotype similar 
to one found in Tregs (60). Tregs are known for their immunosuppressive effect. Even 
though these cells release soluble factors, it is documented that they also act in a cell-
cell contact manner in order to perform their immunosuppressive effect and 
programmed death-1 receptor (PD-1) is known to be one of the molecules involved. 
PD-1 prevents T cells activation, decreasing autoimmunity and enhacing self-
tolerance. MSCs increase IL-10 and TGF-β1 secretion in cocultures - TGF-β1 
regulates the growth, proliferation, differentiation of cells and apoptosis - and 
upregulate PD-1 expression on Tregs cell surface, enhancing Tregs’ 
immunoregulatory capacity (61). 
 
4.3 Immunomodulatory effects of MSCs on B cells 
B cells development occurs in BM and it depends on the production of 
cytokines capable of supporting B cells survival and proliferation. Corcione studied if 
BM-derived MSCs affect the function of mature B cells and concluded MSCs are 
capable of inhibiting B cells proliferation, differentiation into antibody-secreting cells 
and chemotaxis in a dose dependent manner. They also demonstrated that when B 
cells interact with MSCs, the former do not enter apoptosis but stop at the G0-G1 
phases of the cell cycle. Corcione has also proved MSCs exert their effect by 
releasing soluble factors after direct cross-talk with B cells. In fact, data acquired by 
Corcione suggested B cells release activation signals that stimulate MSCs suppressive 
action. However, MSCs do not affect B cells APC function (62).  
It is also known MSCs stimulate immunoglobulin (Ig) secretion by B cells in a 
dependent-contact manner. However, upon B cells activation MSCs reduce Ig 
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production, indicating that in an ongoing infection B cells antibody production may 
be decreased by great amounts of MSCs (63). 
    However, one study reported that primed MSCs increase the expression of B 
cell activation factor (64). In fact, MSCs need to be stimulated by IFN-γ, TNF-α and 
TLR3 in order to perform their immunosuppressive functions on T lymphocytes. 
TLR2, TLR3 and TLR4 are the most expressed in MSCs and when TLR agonists, 
namely TLR4 activates MSCs, they increase B lymphocytes proliferation. B cell-
activating factor (BAFF) is crucial to B lymphocytes generation, differentiation and 
maturation. It is known that TLR4-priming in MSCs has great impact in BAFF 
expression and, consequently regulates B lymphocyte proliferation (64).  
 
4.4 Immunomodulatory effects of MSCs on NK cells 
Upon interaction with MSCs, NK cells begin to express the activation Ag 
CD69 and to release IFN-γ and TNF-α. So NK cells activation by MSCs is a process 
involving lymphocyte function-associated antigen 1 (LFA-1)/ICAM-1 interaction and 
the NKp30 receptor. LFA-1 is found in cells from the immune system and recruits 
these cells to the site of infection. LFA1 binds to ICAM-1 on APCs, acting as an 
adhesion molecule and promoting T cells differentiation. Newsworthy, NK cells in 
different activation status use different triggering receptors, like NKp30 or NKG2D, 
to interact with MSCs (65). As referred previously, MSCs can also supress the 
generation of cytolytic activity from DCs and, consequently the production of 
cytokines. However, IL-2 – activated NK cells can kill both allogeneic and 
autologous MSCs (42).  
Interestingly, NK cells can lyse MSCs depending on which ligand connects to 
the NK receptors (38). Actually, NK cells effector functions are regulated by the 
presentation of receptors in the cell surface that can either activate or inactivate these 
cells. Usually when NK cells are exposed to IL-2, they begin to express activating NK 
receptors that are correlated with NK cells function. Resting NK cells do not 
proliferate in response to IL-2 or IL-15 in the presence of MSCs. IL-2 and IL-15 
induce NK cells proliferation. However, MSCs show little effect in activated NK cells 
proliferation (38).  
MSCs mediate their actions upon NK cells through the release of IDO and 
PGE2 that act synergistically. More specifically, MSCs through IDO and PGE2 
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inactivate surface expression of both receptors involved in NK cells activation and 
molecular markers of activated NK cells (42). 
Some of the information referred above was obtained due to studies that 
addressed MSCs’ immunosuppressive mechanism. These studies were important not 
only to understand the mechanisms employed by these cells, but were also important 
to identify which proteins characterize MSCs. Consequently, new targets for 
therapeutics intervention were discovered. Many proteomics studies have been 
conducted in turn of MSCs. These studies are important to identify new proteins that 
are important to characterize MSCs, as well as new targets for therapeutics 
intervention. Moreover, proteomics provided some information regarding which 
mechanisms and molecules are employed by MSCs during its differentiation into new 
tissues or when they are exerting their immunomodulatory effects. However, further 
data concerning MSCs immunomodulatory mechanisms and differentiation pathways 
is necessary to obtain, before these cells became completely accepted by the scientific 
community as a safe and completely reliable biological therapy. Lipidomics can 
provide some of the remain unknown information, once lipids are one of the main 
components of the cells and their metabolism is highly regulated and changes 
according to cells’ different stages. Moreover, lipidomics can provide reliable 
markers to identify MSCs and to assess their differentiation state and their 
immunomodulatory capacity. 
 
5. Lipidomics 
 Due to improvements in genomics and proteomics, it became possible to 
sequence genes and identify several proteins and their functions. In the last few years, 
a new metabolomics field called Lipidomics has been explored (66,67). Each lipid 
class has specific functions and take part in different metabolic and signalling 
processes, it is important to analyse differences of specific lipid species in different 
pathways. This is one of the reasons that justifies the exponential interest in 
lipidomics. Lipidomics refers to ‘the systems-level analysis of lipids and their 
interacting moieties’. However other definitions claim that lipidomics goes beyond 
lipids characterization, involving also understanding how lipids interfere in all cellular 
pathways (Figure 4) (68). 
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Figure 4.  Lipidomics – different lipids analysis. A cell’s genome encodes for proteins that along 
with environmental factors account for the different metabolites found in a cell. Due to important 
advances, it is possible to study these different scales both qualitatively and quantitatively.  
 
Initial lipidomic analyses relied in analytical techniques with low resolution 
and sensitivity, such as thin-layer chromatography. The advances regarding 
lipidomics studies appeared later because only recently researchers have realized 
lipids can be a part of the etiology of some diseases. Furthermore, researchers merely 
now recognize the importance of studying the metabolism of molecular lipids and 
lipid classes, in order to complete understand a specific pathway involved in cell or 
tissues homeostasis (67,68). This field of research has also improved due to novel 
advances achieved regarding new mass spectrometric techniques and established 
theories on the structural and functional organization of biological membranes (67). 
These recent advances have provided us with the possibility to study lipids at the 
molecular level, becoming possible to study complex lipid mixtures in a high-
throughput manner and pathways involving lipids. These developments also allow us 
to analyse how lipids interfere in cell signalling and how a cell’s lipidome changes 
according to different cell stages. Therefore, lipidomics analysis can be applied to 
obtain biomarkers capable of acting as quality control markers (66). 
However, performing and applying a lipidomic approach is not simple because 
biological lipids are a very diverse group of compounds (Figure 5) and cell’s lipidome 
is very complex. Lipids are a very wide group of molecules. They are one of the main 
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constituents of cells membranes and organelles and they regulate many biological 
processes. The majority of lipids are found in biological membranes and different 
lipid compositions leads to membranes with different properties. This wide group of 
molecules also form the ideal media for the implementation of membrane proteins 
and the interaction, in the membranes, between protein and lipids defines the fluidity 
of biological membranes. The pathways that control membranes’ lipid composition 
are tightly regulated by different extracellular receptor-regulated pathways according 
to the cells’ state (68). Moreover cells exert great efforts to maintain lipid 
homeostasis, once lipids are not equally distributed among organelles and even the 
two leaflets of biological membranes have different relative amounts of each lipid 
class (69).     
Lipids’ most defining characteristic is their insolubility in water. However, 
some lipid classes, as glycosphingolipids are soluble both in water and organic 
solvents, becoming necessary to find another criteria besides their solubility to define 
them. Back in 2003, the LIPID MAPS consortium has defined as hydrophobic or 
amphiphilic small molecules that arise from complete or partial condensation of 
ketoacyl or isoprene subunits (69). 
 
 
Figure 5. Schematic representation of the main lipids found in cells. (Adapted from (66)). * One or 
more saccharide groups. 
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In mammalian cells, it is possible to find between 30 to 60 different fatty acids 
attached to the lipids. The fatty acyl chains have between 12 and 26 carbons, with up 
to six double bonds and they can also have hydroxyl groups attached. Once fatty acids 
can have chains with variable length, different number and position of double bonds, 
they account for the huge diversity found among lipids (69).    
According to their structure, lipids perform different functions. For example, 
fats and oils are mainly used to store energy, while phospholipids and sterols are the 
principal structural elements in biologic membranes. Other lipids act as enzyme 
cofactors, electron carriers, light-absorbing pigments, hydrophobic anchors for 
proteins, “chaperones”, emulsifying agents, hormones and intracellular messengers 
(70). Despite lipids represent a very structurally diverse class of molecules, their 
defying characteristic comes from one structural effect all lipids share, namely a main 
domain of hydrophobic molecules. Usually this domain corresponds to long 
hydrocarbon chains or multiple linked rings (66). 
 Glycerophospholipids are the main component of biological membranes and 
in a lipid extract can exist up to approximately 10 000 different molecular 
glycerophospholipids species (69). Structurally, they are composed by two fatty acids 
ester-linked to a glycerol’s first and second carbon and glycerol’s third carbon is 
attached through a phosphodiester linkage to a polar or charged group. All 
glycerophospholipids are formed from phosphatidic acid (PA). Structurally, PAs have 
a glycerol blackbone and, usually, at glycerol’s first carbon is attached a saturated 
fatty acid, at its second carbon is bonded an unsaturated fatty acid and the third 
carbon has a phosphate group attached. PA is a minor component of the cells and it is 
present mostly in the inner leaflet of biological membranes. PA also interferes with 
membrane curvature and it acts as a signalling lipid, recruiting the appropriate 
cytosolics proteins according to the biological membrane (70). According to the polar 
group, also called, polar head group attached to the glycerol, glycerophospholipids 
form different classes with different functions (66).  
Phosphatidylglycerols (PGs) are one of the main phospholipid classes of the 
lung surfactant. However, PGs are present in mammalian tissues mainly because they 
are cardiolipins (CLs) precursors (70). In mammalian cells CLs are found mostly in 
the inner leaflet of mitochondrial membrane, where they are involved in the 
generation of cellular energy in the form of ATP (69,71). 
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Phosphatidylcholines (PCs) contain a choline molecule attached to glycerol’s 
third carbon and are the main phospholipids of biological membranes in most animal 
tissues. PCs compose almost totally the outer leaflet of the plasma membrane. PCs act 
as precursor for sphingomyelin, PA, lysophosphatidylcholine and platelet-activating 
factor (66). Phosphatidylethanolamines (PEs) represent the second most abundant 
phospholipid class found in biological membrane from mammalian cells. PEs are in 
charge of fusion and maintenance of the functional structure of integral membrane 
proteins. PEs also interfere with membrane proteins conformation and functions (66). 
Phosphatidylserines (PSs) are present in lower amounts in biological membrane from 
mammalian cells. Along with phosphatidylinositol (PI) and PE, PSs are in the inner 
leaflet of the plasma membrane. PSs act as a signalling molecule because when they 
are found in the outer leaflet, apoptotic pathways are activated. PSs are also an 
essential cofactor and activator of protein kinase C (66). PIs are a minor class of the 
membrane glycerophospholipids and are only found in eukaryotes. They act as 
precursors of secondary messengers (66). Moreover, PI and its phosphorylated 
derivates interfere in the cell structure and metabolism. PI 4,5-bisphosphate saves 
messenger molecules that will be release inside the cell as a response to extracellular 
signals. When PI 4,5-bisphosphate is hydrolysed, it originates two intracellular 
messengers: inositol 1,4,5-trisphophate (IP3) that is soluble in water and 
diacylglycerol that remains in the plasma membrane. IP3 acts upon endoplasmic 
reticulum and triggers Ca2+ release to the cytosol. High levels of Ca2+ associated with 
diacylglycerol, activate protein kinase C (70). 
 Lysophosphatidylcholines (LysoPCs) result from the action of the enzyme 
phospholipase A2 upon PCs.  LysoPCs activate the expression of many genes 
involved in inflammatory responses, for example in endothelial and T cells. LysoPCs 
are found in cell’s plasma and help transporting polyunsaturated fatty acids and 
cholines to tissues. However, if LysoPCs levels get out of control pathological 
conditions, such as ischemia and atherosclerosis can arise (66). 
 Sphingolipids are another of the main lipids classes. Unlike 
glycerophospholipids, sphingolipids have a sphingosine backbone and no glycerol. 
The amino group at sphingolipids’ second carbon is bonded to a fatty acid in amine 
linkage. Sphingolipids differ from each other according to the polar head group 
attached to the first carbon, either by a glycosidic linkage or a phosphodiester. 
Sphingolipids are the fourth larger class of membrane lipids (70). 
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 Sphingomyelins (SMs) are one of the three subclasses of sphingolipids and 
contain phosphocoline or phosphoethanolamine as polar head group. Due to SMs 
polar head, they are also considered phospholipids, along with glycerophospholipids. 
Structurally and physiologically, SMs resemble PCs. SMs are also present in animal 
biological membranes, especially in the outer leaflet. SMs have high affinity towards 
cholesterol and usually are located together in specific sub-domains or lipid rafts of 
membranes. Moreover, it seems SMs control cholesterol distribution in membranes 
(70). 
In animals, SMs are the major source of ceramides, which are necessary to 
trigger apoptosis, along with other metabolic pathways. Sphingomyelins also seem to 
be involved in the activity of some membrane-bound proteins, including those of 
some ion channels and receptors (70). SM and ceramides found in membranes are 
powerful regulators of protein kinases (70).  
 
6. Lipidomic Approach 
Cell’s lipidome is very complex and can encompass approximately between 
180 000 and 200 000 different lipid species. For this reason, it is necessary very 
precise steps in order to be correctly analysed (69). Thus lipid isolation from tissue or 
cells is the first procedure to be executed. Lipid isolation methods rely on lipids high 
solubility in organic solvents. Analysis of lipids previously extracted is the following 
method to be applied. This can be made directly, using mass spectrometry (MS), or 
after chromatographic separation. Using phosphorous assay that measures inorganic 
phosphorous and/or additional analysis by MS, it becomes possible to identify and 
quantify each phospholipid species present in the sample after phospholipids classes 
separation usually by thin layer chromatography (TLC). These steps provide a ‘lipid 
profile’ of the cell, i.e. an inventory of the lipids present in the cell or tissue under 
investigation. Different functional states of the cells or tissue under investigation are 
reflected in different ‘lipid profile’ obtained after applying this steps, providing us 
with information regarding which pathways are affected. This step is known as 
pathways analysis (67) (Figure 6). Therefore, according to the main goals of this 
master thesis, we hypothesize MSCs subjected to different stimuli will produce 
different ‘lipid profiles’ and this information may be useful to understand which 
metabolic pathways are affected. 
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Figure 6. Schematic representation of several steps during lipidomic approach 
 
6.1 Lipid Isolation  
 Lipid isolation from tissues is the first step to accomplish before further 
analysis. The lipid extract must be free of non-lipid contaminants (72). The solvent or 
mixture of solvents used must be quite polar, in order to break the interaction between 
lipids and cell membranes or lipoproteins. Usually these interactions are weak and 
hydrophobic or are Van der Waals forces. However, the solvent can not be totally 
polar to prevent chemical reactions with lipids. In resume, the solvent must 
simultaneously interfere with both the hydrophobic and polar interactions (72).  
The first lipid extraction methods were developed by Folch in 1957 (73) and 
later in 1959 by Bligh & Dyer (74). These are capable of isolating both neutral and 
polar constituents of lipids and modified forms of these methods are still widely used 
nowadays. These methods are based on a mixture of chloroform and methanol (2:1) 
(v/v) and following wash with salt solution or adjusting the amount of water (75,76). 
Most of the contaminating material can be removed using this mixture. Once the ratio 
of chloroform-methanol to tissue is higher than 17:1, the water manages to remain in 
an independent phase. Yet, the solution of chloroform and methanol is toxic, irritant 
to the skin and neither one of the solvents are totally stable.  Many solvents or 
solvents combinations can be used. However, they must ensure that there is no 
enzymatic or lipolytic activities (72). Despite the technique chosen, all ensure the risk 
of hydrolysis or autoxidation of lipids is minimized (72).  
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The extraction method is chosen according to the nature of the tissue matrix, 
its nature (animal, plant or microbial origin) and the analytical method used. In this 
study, a modified version of the method developed by Bligh & Dyer will be used. In 
this modified version, the pellet is ressuspended in a solution of chloroform and 
methanol (1:2) (v/v) and the mixture is left in ice for 30 minutes.  After this time, 
chloroform is added, followed by extra pure water that will induce the separation 
between the aqueous and the organic phases. The lipids will be dissolved in the 
organic phase (bottom) due to their polarity. The polarity of lipids is controlled by 
their hydrophobic hydrocarbon chains of fatty acids and any possible hydrophilic 
groups, namely phosphate or sugar residues (72). 
 
6.2 Lipidomic Analysis  
 After applying the most adequate extraction method, it remains a lipid extract 
from cells, tissues or body fluids. Chromatographic separation on silica thin-layer 
plates (77) or silica columns can be applied to fractionate lipids extracts before further 
and more thorough analysis (78). After applying separations techniques, it is possible 
further identification and quantification of each molecular species (67). 
 There are several chromatography techniques that can be used for the analysis 
of lipids: TLC, gas chromatography (GC), liquid chromatography (LC) and high-
performance liquid chromatography (HPLC). These techniques can be coupled with 
MS and act as pre-separation techniques (67). In this study, HPLC will be the 
technique employed. This technique allows the separation of different lipids classes as 
PEs, PGs, PCs, among others (78). After the different lipid classes have been 
chromatographically separated, the lipid extract is introduced to MS for further 
analysis. This approach is known as targeted lipidomics because the aim is to quantify 
lipids from a specific class (78). 
 When performing MS of lipids samples, the most common used ionization 
technique is electrospray ionization (ESI). ESI is a soft, non-destructive technique that 
generates positive and negative molecular lipid ions with minimal in-source 
fragmentation (79). ESI can be used in its positive mode (ESI+) to analyse major 
phospholipids and sphingolipids classes. However, some phospholipids classes, such 
as PIs, PSs and PAs are properly analysed using the negative ion mode (ESI-) (80). 
Tandem mass spectrometry analysis allows the confirmation of the structural details 
of each molecular species, such as information regarding polar head group and fatty 
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acid substitution. It is also aimed to study the profile of fatty acids. To do so, fatty 
acids will be assessed after transmethylation, followed by analysis of fatty acids’ 
methyl esters by gas chromatography coupled with mass spectrometry and gas 
chromatography coupled with a flame ionization detector.  
 
7. Lipidomics of Mesenchymal Stromal Cells 
 As referred above, lipids are one of the main constituents of mammalian cells. 
Most lipids are found in biological membranes, so biological membranes’ 
characteristics and properties depend on the different lipids that compose the 
membranes. The metabolism that controls the different lipids found in membranes is 
highly regulated and it depends on the cell’s state. In fact, changes in the lipids 
present in the membranes regulate enzymatic activity, channels and transport of 
proteins (68). In addition, lipidomics profiles provide information regarding the 
global lipid concentration of cells, tissues or body fluids during specific physiological 
states (78). 
For these reasons, several studies concerning cell’s lipidome have aroused in 
order to gain better insight over different diseases and cells markers and also 
correlated with cells of the immune system. In fact, lipidomic approach was used to 
characterize the molecular diversity of the main classes of phospholipids and 
sphingolipids found in DCs and to identify changes in DCs’ lipidome during 
lipopolysaccharide-induced maturation (68). A lipidomic approach was also 
performed to identify the main lipid classes and their species in circulating blood 
cells. Performing this analysis in cells from healthy donors allowed to identify 
specific characteristics of individual blood cells. Moreover, detailed knowledge of 
lipid profiles of circulating blood cells provided important new information regarding 
lipid abnormalities on diseases and perception about how these pathologies are 
affected by lipids (81). 
Up to date many few studies were conducted regarding stem cells’ membrane 
lipids and alterations in these cells’ lipids profile have not been thoroughly analysed. 
Despite glycosphingolipids and signalling lipids have been analysed, 
glycerophospholipids have not received much attention (82). Concerning MSCs, few 
studies have been conducted. However these studies can be very helpful since 
characterization of these type of cells is required for their application as biological 
therapy. 
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When culturing MSCs to apply them as a biological therapy, it remains 
unknown how many cell doublings can these cells undergo before they became 
malignant or lose their differentiation ability. Kilpinen was the first to address this 
question and did so performing a lipidomic study regarding MSCs (82). More 
specifically, Kilpinen’s aim was to compare glycerophospholipids profile between 
MSCs from young and old donors and how sequential expansion of the cells affected 
these profiles. In order to accomplish these objectives, MSCs were cultured in a 
medium supplemented with FBS and MSCs’ total lipids were extracted using Folch 
extraction method. According to this study, there are no significant differences 
between the percentages of phospholipids classes present in MSCs from young or old 
donors. Indeed, in average PC is the most abundant class (41-46%), followed by PE 
(34-38%), PS (5-8%) and PI (4-8%). Interestingly, the average amount of PC, PS and 
PI resembles the values usually found in human fibroblasts. The relative amount of 
PE found was much higher than what is usually found in human fibroblast or 
mammalian cells. However, the percentages of both PC alkyl and PE alkenyl were 
significantly different in MSCs from late passages when comparing MSCs from 
young and old donors. Besides, the ration PI/PS was higher in MSCs from late 
passages than in MSCs from previous passages (82). 
Kilpinen also studied the most common species within the different 
phospholipids classes. Regarding the most abundant PC species, in descending order, 
they are 34:1, 36:2, 36:1, 38:4; in the case of PE class, the most abundant classes, in 
descending order, they are 38:4, 36:1, 36:2, 40:5, 38:5 and 34:1. PS species 36:1, 40:5 
and 40:6 are, in descending order, the most abundant. 38:4 represents almost 50% of 
the total PI species existent. In this study, Kilpinen has also studied changes in 
individual lipid species among MSCs from different passages. Among PC diacyl 
species, the molar percentage of 38:4, 36:4 and 36:1 is higher in MSCs from later 
MSCs, while the opposite occurrs for the species 34:1, 34:2 and 36:2. The PE diacyl 
species profiles have higher amounts of 38:4 and 36:4 species and fewer amounts of 
monounsaturated species, such as 34:1 and 36:1 in MSCs from later passages. In 
general, the levels of PC 34:1 and PE 36:1 are enhanced in MSCs from young donors 
compared with MSCs from old donors. Kilpinen was able to conclude that MSCs that 
experience more expansions in culture suffer harmful changes in the phospholipid 
composition of their membranes, which affects lipid signalling and it can lead to 
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impaired functionality. Therefore biosynthetic precursors in membranes can be used 
as indicators of cell functionality (82).  
Even though this work portrays great advances regarding MSCs’ lipidome, it 
did not provide specific biological markers capable of identifying MSCs neither 
provided further insight regarding MSCs’ mechanism.  Furthermore, these studies 
have focused in MSCs cultured in media supplemented with FSB and there is no 
study that characterizes MSCs cultured in xeno-free media. Characterization of xeno-
free media-cultured MSCs will allow applying these cells in many therapies without 
arising concerns regarding patient’s safety. Thus, future work is needed to fulfil these 
gaps in literature. 
 
8. Objectives 
 In order to gain new insights regarding MSCs’ lipidome, the main goals of the 
present thesis are:  
a) To study MSCs’ lipid profile  
b) To identify the variation in MSCs’ lipidome when  
a. MSCs are cultured in two different medias and when 
b. MSCs are subjected to pro-inflammatory stimulus.  
c) Besides, it is also aimed to better understand how MSCs exert their 
immunomodulatory ability and which biological markers may possibly 
be analysed in order to ensure only powerful immunomodulatory 
MSCs are being collected and employed as a biological therapy in 
inflammatory diseases.  
 To achieve these aims, MSCs will be cultured in both a media containing an 
animal serum and in a media xeno-free, i.e. a synthetic media. MSCs from both 
cultures were further subjected to pro-inflammatory studies. MSCs were provided by 
CELL2B. 
Lipidomic analysis will be performed using HPLC-MS and MS/MS of the 
total lipid extracts, along with GC-MS and GC-FID analysis of the fatty acid profile. 
This approach will allow identifying which phospholipids classes and species were 
present in MSCs from all conditions. With this data, it becomes possible to 
understand how the relative amounts of phospholipids classes and species change 
according to the culture conditions and can be used to molecular phenotyping these 
type of cells. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. Material and Methods
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Material and Methods 
1. Chemicals 
Phospholipid internal standards 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(dMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (dMPE), 1,2-
dimyristoyl-sn-glycero-3-phospho-(1-rac-glycerol) (dMPG), 1,2-dimyristoyl-sn-
glycero-3-phospho-L-serine (dMPS), tetramyristoylcardiolipin (TMCL), 1,2-
dipalmitoyl -sn-glycero-3-phosphatidylinositol (dPPI), 1,2-dimyristoyl--sn-glycero-3-
phosphate (dMPA), 1-heptadecanoyl-2-hydroxy-sn-glycero-3phosphocholine (LPC) 
were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Chloroform, 
methanol and hexane from Fisher scientific (Leicestershire, UK); all were of high 
HPLC grade and were used without further purification. All the other reagents and 
chemicals used were of the highest grade of purity commercially available. The water 
was of miliQ purity filtered through a 0.22-mm filter (Millipore, USA). 
 
2. Collection of Bone Marrow 
Human bone marrow (hBM) aspirates were either commercially obtained from 
(Lonza) or from donations from “Instituto Português de Oncologia (IPO) de Lisboa, 
Francisco Gentil, EPE or IPO-Porto”. Samples were obtained from healthy donors 
(age 20-40 years old) after informed consent. 
 
3. Isolation of hMSCs from Bone Marrow 
BM mononuclear cells (MNC) were isolated using Sepax S-100 system 
(Biosafe), according to manufacturer’s instructions. The Sepax cell processing system 
uses a rotating syringe technology that provides both separation through rotation of 
the syringe chamber (centrifugation) and component transfer through displacement of 
the syringe piston. The Sepax system allows the automated processing of blood 
components in a functionally closed and sterile environment. The system uses Ficoll 
(GE Healthcare) to separate the low density BM-MNC, and saline solution, NaCl 
0.9% (Labesfal), to wash the cells. BM-MNCs were then plated in Corning® 
Polystyrene Tissue Culture Flasks, using Dulbecco’s Modified Essential Medium 
(DMEM, Gibco) supplemented with 10% Fetal Bovine Serum MSC qualified (FBS, 
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Gibco) or with xeno-free medium at a density of 600 000 MNC/cm2. Cell counting 
was performed using trypan blue (Gibco) exclusion assay. Culture medium was 
changed every 3/4 days and cells were passaged when reached a confluence of 70-
80%. 
 
4. Cell cryopreservation 
After harvesting and counting, cells were centrifuged and resuspended in 
defined cryopreservation medium, Synth-a-Freeze™ (Gibco). The cell suspension 
was transferred to cryovials and maintained at -80ºC storage freezer. In case of long-
term cryopreservation, cells were transferred to liquid nitrogen. 
 
5. Cell Thawing and Seeding  
Cryoval containing MSCs were thawed in a 37 ºC water bath. The vial content 
was trnsfered to a conical tube previously filled with medium DMEM (Gibco) 
supplemented with FBS (Sigma-Aldrich) 10% (v/v) or with xeno-free medium in 1:10 
dilution. After centrifugation at 1250 rpm for 7 min, the supernant was discarded and 
the cell pellet ressuspended in culture fresh medium. From the homogeneous cell 
suspension, 10 µL were removed to perform cell count and viability analysis, using 
the Trypan Blue exclusion Method (83). Briefly, 10 µL of cell suspension were 
placed in a microplate and 10 µL of Trypan Blue Stain (Gibco) were added and mixed 
very well. Then 10 µL of the previous mix were applied into a hemacytometer. Using 
a microscope the viable cells (unstained) and nonviable cells (stained blue) were 
count separately in the hemacytometer. Cells were seeded at 3000 cells/cm2 density in 
tissue culture flasks. Afterwards the cell vessels were incubated in a CO2 incubator at 
37 ºC, 5% CO2. The culture medium were changed every 3 to 4 days until MSCs 
cultured reached 70-80% confluency. At this point MSCs cultured were either 
stimulated with IFN-γ (R&D System) and TNF-α (Sigma-Aldrich) or harvested. 
 
6. MSCs culture stimulation 
 Once MSCs cultures reached 70-80% confluency, 500 U/mL of IFN-γ (R&D 
System) and 10 ng/mL of TNF-α (Sigma-Aldrich) were added to the cells cultures. 
Then the cultures were incubated with the cytokines for 48 hours at 37 ºC, 5% CO2 
and harvested. 
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7. MSCs harvesting 
 The medium from the culture vessel was discarded and the flask washed with 
10 mL DPBS. TrypLETM (Gibco) were added to detach cells from culture dish and 
dissociate cell aggregates. Then the culture vessel was incubated in CO2 incubator at 
37 ºC for 7 min. Once it was confirmed cells detachment from the surface, culture 
medium were added, in order to inactivate the enzyme and the mixture were 
transferred to a conical tube.  Afterward the mix was centrifuged at 1250 rpm for 7 
min and the supernant discarded. The cell pellet was ressuspended in culture fresh 
medium and 10 µL were removed to perform cell count and viability analysis using 
Trypan Blue exclusion Method. The cell suspension was again centrifuged at 1250 
rpm for 7 min, the supernant discarded and the cells stored at -80 ºC until further 
analysis. 
 
8. Phospholipid Extraction 
Cell pellets from MSCs cultured in DMEM or xeno-free medium with no 
stimulus or cultured under TNF-α and IFN-γ were ressuspended in 1 mL miliQ water. 
Phospholipids were extracted from all cell pellets by the Blight and Dyer method 
(74). Briefly, 2.50 mL of MeOH were added to the homogenized tissues and well 
vortexed. Subsequently 1.25 mL CHCl3 were added to previous mix and incubated in 
ice for 30 min. Afterward 1.25 mL of CHCl3 and 1.25 mL of H2O were added and 
mixed well. Then the suspension was centrifuged at 1,000 x g, 5 min, at room 
temperature, using a centrifuge Mixtasel Centrifuge (Selecta), and two phases were 
obtained: the aqueous phase on top and the organic phase below, where lipids were 
retrieved. The extracts were dried under nitrogen stream and stored at -20ºC. 
 
9. Separation of phospholipids classes by TLC 
PL classes were separated from total lipid extract by TLC using a plate of 
silica gel 60 with concentration zone 2.5x20cm. Previous to TLC separation, the plate 
were washed in CHCL3:MeOH (1:1 v/v) and treated with boric acid in ethanol (2.3% 
w/v). The plate with spots containing about 30 µg of sample were developed in a 
mixture of solvents CHCl3:MeOH:H2O:tN(CH2CH3) (30:35:7:35 v/v/v/v). The 
phospholipid spots were revealed sprinkling the TLC plate with a primuline solution 
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(50 µg/100 mL acetone: water, 80/20 v/v) and visualized with UV lamp (λ=254 nm). 
Phospholipid spots were identified after comparison with phospholipid standards. 
Then the phospholipid spots were scraped from the plate and quantified using the 
phosphorous assay. 
 
10. Quantification of Phospholipids classes using phosphorous assay 
In order to determine the amount of phospholipid in each extract and the 
amount of phospholipid class separated by thin layer chromatography (TLC), a 
phosphorous quantification method was performed according to the protocol of 
Bartlett and Lewis (84). Briefly, 125 µL of percloric acid (70% m/v) were added to 
the samples, which were incubated 60 min at 180 ºC in a heating block (Stuart, U.K.). 
825 µL of miliQ H2O and 125 µL of ammonium molybdate (2.5 g ammonium 
molybdate/ 100 mL H2O) and 125 µL of ascorbic acid (10 g ascorbic acid/100 mL 
H2O) were added to all samples and vortexed following the addition of each solution. 
Then the samples were incubated in a bath at 100 ºC for 10 min. Additionally 
standards were prepared using 0.1 to 2 µg of phosphate, which suffered the same 
treatment as the samples. The absorbance of samples and standards were measured at 
793 nm, in a microplate reader (Multiscan 90, ThermoScientific). 
 
11. GC-FID conditions 
 Fatty acid methyl esters (FAMEs) were obtained upon transesterification of 
lipid extracts according to the procedure described by Aued-Pimentel et al. (85). 
Briefly, dried lipid extracts (30 µg of total phospholipid) were ressuspended in 1 mL 
n-hexane. A KOH solution in methanol (2 M) was added (200 µL), followed by 1-2 
min of intense vortex-mixing. A saturated NaCl solution (2 mL) was then added. 
After centrifugation at 2000 rpm for 5 min (centrifuge Mixtasel Centrifuge (Selecta)), 
the organic phase – upper phase - was collected and dried under a nitrogen stream. 
The resulting FAMEs were dissolved in n-hexane and volumes of 5 µL were analyzed 
by gas chromatography (GC) on a PerkinElmer Clarus 400 gas chromatograph 
(Waltham, MA) equipped with a flame ionization detector (FID) and a DB-1 column 
with 30 m of length, 0.25 mm of internal diameter, and 0.1 µm of film thickness 
(J&W Scientific, Folsom, CA). The oven temperature was programmed from an 
initial temperature of 50 ºC, and hold time of 3 min; a linear increase at 25 ºC/min to 
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180 ºC, and hold time of 6 min; followed by linear increase at 40 ºC/min to 260ºC, 
and hold time of 3 min. The injector and detector temperatures were 220 and 230 °C, 
respectively. The carrier gas was hydrogen and the flow rate was of 1.7 mL/min. The 
peak identification was made on the retention times of each 34 FAME standards (C6-
C24, Supelco 37 Component Fame Mix). 
 Relative abundance of each FAME identified in both conditions was 
determined upon integration of each peak using the equipment’s software. This 
analysis was carried out in triplicate for each sample and three different samples were 
analyzed for each experimental group. 
 
12. GC-MS conditions 
FAMEs were obtained after transesterification of lipid extracts according to 
the method described by Aued-Pimentel et al. (85). Briefly, dried lipid extracts (30 µg 
of total phospholipid) were dissolved in 1 mL n-hexane. A methanolic KOH solution 
(2 M) was added (200 µL), followed by intense vortex-mixing for 1-2 min. Saturated 
NaCl solution (2 mL) was added. After centrifugation at 2000 rpm for 5 min, the 
organic phase was collected and dried under a nitrogen stream. The resulting FAMEs 
were dissolved in n-hexane and volumes of 2.0 µL were analyzed by gas 
chromatography–mass spectrometry (GC–MS) on an Agilent Technologies 6890 N 
Network (Santa Clara, CA) equipped with a DB-FFAP column with 60 m of length, 
0.25 mm of internal diameter, and 0.25 µm of film thickness (J&W Scientific, 
Folsom, CA). The GC equipment was connected to an Agilent 5973 Network Mass 
Selective Detector operating with an electron impact mode at 70 eV and scanning the 
range m/z 50–550 in a 1 s cycle in a full scan mode acquisition. The oven temperature 
was programmed from an initial temperature of 90 °C, a linear increase to 220 °C at 
14.4 °C min−1, followed by linear increase at 10 °C min−1 to 240 °C, then at 5 °C 
min−1 to 250 °C. The injector and detector temperatures were 220 and 280 °C, 
respectively. Helium was used as carrier gas at a flow rate of 0.5 mL min−1. The 
relative amounts of FAs were calculated by the percent area method with proper 
normalization considering the sum of all areas of the identified FAs. 
 
13. HPLC - Electrospray mass spectrometry conditions 
To identify the molecular phospholipid species and their changes in MSCs 
under pro-inflammatory stimulus, phospholipid classes were separated by hydrophilic 
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interaction liquid chromatography (HILIC)-MS, using an HPLC system (Waters 
Alliance 2690) coupled with and electrospray (ESI) linear ion trap mass spectrometer 
(ThermoFinningan, San Jose, CA, USA). The mobile phase A consisted of 55% (v/v) 
acetonitrile, 25% (v/v) of methanol and 25% water with 10 mM ammonium acetate. 
The mobile phase B consisted of acetonitrile 60%, methanol 40% with 10 mM 
ammonium acetate. 25 µg of total lipid extract were diluted in 90µL of mobile phase 
B and the reaction mixture was introduced into Ascentis Si HPLC Pore column (15 
cm x 1.0mm, 3 µm) (Sigma-Aldrich). The solvent gradient was set as followed: 
gradient began with 0% of A and linear increase of 100% A during 20 min, and held 
isocratically for 35 min, returning to the initial set up after 5 min. The follow rate 
through the column was 16 µL/min, obtained using a pre-column split (Acurate, LC 
Packings, USA), and it was redirected to a LXQ linear ion trap mass spectrometer 
(ThermoFinningan, San Jose, CA, USA) by a capillary (0.350 × 0.150 mm) of 70 cm 
length. The LXQ linear ion trap mass spectrometer was operated in negative-ion 
mode. Typical ESI conditions were as follows: electrospray voltage, 4.7 kV; capillary 
temperature, 275 °C; and sheath gas flow, 25 units. To obtain the product-ion spectra 
of the major components during LC experiments, cycles consisting of one full scan 
mass spectrum and three data-dependent MS/MS scans were repeated continuously 
throughout the experiments with the following dynamic exclusion settings:  repeat 
count 3; repeat duration 30s; exclusion duration 45s. LC-MS was performed with 
internal standards to confirm and quantify the ion differences present in the spectrum 
according to the Lipid Maps methods (86). The PL standards chosen were PC (dMPC 
14:0/14:0), PS (dMPS 14:0/14:0), PI (dPPI 16:0/16:0), PE (dMPE 14:0/14:0), 
phosphatidic acid (PA) (dMPA 14:0/14:0), cardiolipin (CL) (14:0/14:0/14:0/14:0), 
LPC (19:0) and phosphatidylglycerol (PG) (dMPG 14:0/14:0). 
  Data acquisition and treatment of results was done with Xcalibur data system 
(V2.0) (87). Relative quantitation of individual phospholipid species was determined 
by he ratio between the area of reconstructed ion chromatogram of a given m/z value 
against the area of the reconstructed ion chromatogram of the respective class (88). 
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14. Statistical Analysis  
Results were represented as means ± standard error (SD). One-way analysis of 
variance (ANOVA) with the Bonferroni post-hoc test was used to determine 
significant differences among samples. A value of p<0.05 was considered significant. 
Statistical analysis was performed using GraphPad Prism 5 for Mac OS X (GraphPad 
Software, San Diego, CA, USA; www.graphpad.com). 
 
  
 
 
 
 
 
 
 
 
III. Results
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Results 
1. MSCs cultured in DMEM 
 
1.1 Effects of TNF-α and IFN-γ stimuli in fatty acid profile of MSCs 
In order to evaluate alterations in the FA profile of MSCs after pro-
inflammatory stimulus, FAMES obtained after transesterification of the total lipid 
extracts from both MSCs cultured in DMEM with no stimuli (MSCs_DMEM nstim) 
and MSCs cultured in DMEM under TNF-α and IFN-γ (MSCs_DMEM TNF+IFN) 
were separated and quantified by GC-FID. This approach allowed the identifying 9 
most abundant fatty acids in both samples: myristic acid (C14:0), palmitoleic acid 
(C16:1), palmitic acid (C16:0), linoleic acid (C18:2), oleic acid (C18:1 Δ9 cis), elaidic 
acid (C18:1 Δ9 trans), stearic acid (C18:0), arachidonic acid (C20:4 Δ6) and dihomo-
γ-linoleic acid (C20:3) (Figure 7).  
 
 
Figure 7. Fatty acid profile of total lipid extracts from MSCs cultured in DMEM with no stimuli 
(Nstim) and MSCs cultured in DMEM subjected to TNF-α  and IFN-γ  (TNF+IFN). Relative 
content of the major fatty acids analysed by GC-FID. Values are means ± standard deviation of three 
independent experiments. ***, significantly different from Nstim (P<0.001). 
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The most abundant FAME species in MSCs from both conditions were C16:0, 
C18:1 Δ9 cis, C18:0 and C20:4 Δ6 (Figure 7). Significant differences in the relative 
amount of C16:0 and C18:0 in MSCs fatty acid profile under pro-inflammatory 
stimuli were observed (Figure 7). The presence of TNF-α and IFN-γ caused a 
significant increase in C18:0 levels, while C16:0 levels decreased (Figure 7). No 
significant changes were detected in the levels of the remainder FAME between 
MSCs_DMEM nstim and MSCs_DMEM TNF+IFN. 
 
1.2 Effects of TNF-α and IFN-γ in phospholipid profile of MSCs 
In order to evaluate alterations in the PL profile of MSCs_DMEM TNF+IFN, 
the total lipid extracts of MSCs of both experimental groups were fractionated by 
TLC. Each class was identified by comparison with pure phospholipid standards 
applied in the same TLC plate and relative amount of each PL class observed in TLC 
plate was determined by quantification of phosphate content in each PL spot. This 
approach allowed the separation of six phospholipid classes: sphingomyelin (SM), 
phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylserine (PS), 
phosphatidylethanolamine (PE), and lysoPC (LPC) (Figure 8, A.1 and B.1). The most 
abundant PL class was PC, followed by PE, SM, PS, PI and LPC (Figure 8, A.2 and 
B.2). No significant differences in PLs class content were observed between 
MSCs_DMEM nstim and MSCs_DMEM TNF+IFN. 
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1.3 Analysis of phospholipid molecular profiling in MSCs after TNF-α and IFN-γ 
stimuli by HILIC-MS 
In order to evaluate alterations in the molecular composition of each PL class, 
phospholipid molecular species were identified by HILIC-MS and LC-MS/MS in 
negative mode(89–91). For all six identified PL classes, a phospholipid molecular 
profile was obtained. This analysis was carried out once for each sample and three 
different samples were analysed for each experimental group. PL classes were 
analysed by LC and MS/MS in negative mode. MS/MS interpretation for each ion 
allowed identification of PL molecular species.  
Figure 8. Thin-layer chromatography of total lipid extract obtained from MSCs cultured in 
DMEM with no stimuli (A.1) and MSCs cultured in DMEM subjected to TNF-α  and IFN-γ  
(B.1). Phospholipid standards were also applied: (PC) - Phosphatidylcholine; (PS) - 
Phosphatidylserine; (PE) - Phosphatidylethanolamine; (SM) - Sphingomyelin; (PI) - 
Phosphatidylinositol; (LPC) - Lysophosphatidylcholine. The phospholipid classes were separated by 
thin-layer chromatography and the phosphorous content of each spot was calculated taking in account 
the amount of phosphorous in the total lipid extract. Relative content of phospholipid classes in MSCs 
cultured in DMEM with no stimuli (A.2) and MSCs cultured in DMEM subjected to TNF-α and IFN-γ 
(B.2) in total lipid extract. 
 44 
PC and LPC were identified as [M+CH3COO]- in LC-MS spectra. In both 
conditions the most abundant PC molecular specie was PC(34:1) at m/z 818.2 for 
[M+CH3COO]- ion (Figure 9, A). Also MSCs’ PC molecular profile was much 
similar to one previous reported (82). Significant alterations in MSCs’ PC molecular 
profile were observed comparing MSCs from experimental and control groups. In 
fact, a significant decrease of PC(34:1) at m/z 818.2 specie, along with PC(32:1) at 
m/z 790.2, PC(32:0) at m/z 792.4 and PC(40:6) at m/z 892.3 were found. However, in 
MSCs_DMEM TNF+IFN, a small increase of some other molecular species were also 
observed: PC(36:1) at m/z 846.2 and PC(38:4) at m/z 868.2 (Figure 9, A). PC is the 
major PL class in eukaryotic cells and it is not only the main structural component of 
biological membranes, but it is also involved in signal transduction being precursor of 
signalling molecules (92). 
In the LC-MS negative mode spectra obtained from both MSCs_DMEM nstim 
and MSCs_DMEM TNF+IFN, three [M+CH3COO]- ions attributed to LPC were 
identified (Figure 9, B). In both conditions the most abundant LPC molecular specie 
was LPC(18:0) at m/z 582.3. Comparing LPC profile of both MSCs_DMEM nstim 
and MSCs_DMEM TNF+IFN, a significant increase of LPC(18:0) specie was 
observed (Figure 9, B). LPC is formed in physiological and pathological conditions 
and can be involved in many cellular processes (93). LPC induces secondary 
messengers activation and it interferes with their pathways (94,95) and it is also a 
bioactive lipid that plays a role in inflammatory conditions (96). 
SM were identified as [M+CH3COO]- ions in LC-MS spectra (Figure 9, C). In 
both conditions the most abundant SM molecular specie was SM(34:1) at m/z 761.3. 
In MSCs_DMEN TNF+IFN a significant increase of an sphingomyelin molecular 
specie – SM(34:0) at m/z 763.1 – was identified (Figure 9, C). SM’s assymetric 
molecular structure and hydrogen-bonding properties are essential to its role as 
structural compounds in biological membranes. Moreover, due to SM great ability to 
bind itself to cholesterol, indicates SM’s role as cholesterol distribution modulator 
(97). 
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Figure 9. Percentage of the major phosphatidylcholine (PC) (A), lysoPC (LPC) (B) and 
sphingomyelin (SM) (C) molecular species identified in MSCs cultured in DMEM after LC-MS 
and MS/MS analysis. The results were expressed as percentage obtained by dividing the ratio between 
the peak areas of each molecular species and the respective internal standards and the total of all ratios. 
Values are means ± standard deviation of three independent experiments. ***, significantly different 
from Nstim (P<0.001). **, significantly different from Nstim (P<0.01). *, significantly different from 
Nstim (P<0.05). 
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PE were identified as [M-H]- ions in LC-MS spectra. The most abundant PE 
species previous reported by Kilpinen (82) were also observed in this study. However, 
we also identified two more PE species: PE(36:0) and PE(O-36:5). Significant 
alterations in MSCs’ PE molecular profile were observed comparing MSCs_DMEM 
nstim and MSCs_DMEM TNF+IFN (Figure 10, A). In fact, a decrease of PE(O-38:6) 
at m/z 748.3 and a increase of PE(40:6) at m/z 790.3 were observed in MSCs_DMEM 
TNF+IFN (Figure 10, A). PE comprises about 15-25% of the total biological 
membrane phospholipids. Similar to PC, PE also acts as a structural component of 
membranes. However, PE is also substrate for other metabolic pathways originating 
PS in the reticulum endoplasmic (92,98). 
PS was identified as [M-H]- and the most abundant PS in both conditions was 
PS(36:1) at m/z 788.3 (Figure 10, B). Significant alterations in PS molecular profile 
were observed between MSCs_DMEM nstim and MSCs_DMEM TNF+IFN. For 
MSCs_DMEM TNF+IFN a decrease of PS(40:4) at m/z 838.3 was observed while 
levels of PS(36:1) at m/z 788.3 increased (Figure 10, B). Also in PS profile, PS(36:0) 
was identified, which has not been previously reported. Nevertheless PS most 
abundant species reported by Kilpinen were also observed in this study. PS is present 
in small amounts in cells but is an important signal molecule both inside and outside 
of the cell. In fact, when PS is present in apoptotic cells’ outer leaflet of biological 
membranes, it acts as a signal for phagocytosis (92,98). Moreover, PS has a role in 
targeting intracellular proteins and in maintaining their function (98). 
PI molecular species were identified as [M-H]- ions (Figure 10, C). Three PI 
species – PI(36:0), PI(O-38:6) and PI(40:6) - that have not identified by Kilpinen (82) 
were identified in this study. In both experimental conditions the most abundant PI 
molecular specie was PI(38:4) at m/z 885.3. No significant alterations in MSCs PI 
molecular profile were observed between MSCs_DMEM nstim and MSCs_DMEM 
TNF+IFN (Figure 10, C). PI comprises about 10-15% of cellular phospholipids and 
has an important role as precursor for secondary messengers, namely PIPs. 
Glycosylphosphatidylinositol also acts as an anchor for soluble proteins (92). 
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Figure 10. Percentage of the major phosphatidylethanolamine (PE) (A), phosphatidylserine (PS) 
(B) and phosphatidylinositol (PI) (C) molecular species identified in MSCs cultured in DMEM 
after LC-MS and MS/MS analysis. The results were expressed as percentage obtained by dividing 
the ratio between the peak areas of each molecular species and the respective internal standards and the 
total of all ratios. Values are means ± standard deviation of three independent experiments. ***, 
significantly different from nstim (P<0.001). **, significantly different from nstim (P<0.01). *, 
significantly different from nstim (P<0.05). 
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In resume, the same molecular species were found for each PL class either in 
MSCs_DMEM nstim and MSCs_DMEM TNF+IFN. However, significant differences 
in the relative amount of some molecular species were found for all PL classes - 
except for PI - between MSCs_DMEM nstim and MSCs_DMEM TNF+IFN (Table 
1). Table 1 summarizes which PL molecular species’ levels vary in MSCs cultured in 
DMEM (MSCs_DMEM) under pro-inflammatory environment. 
 
Table 1 - Summary of all identified PL molecular species whose amounts were 
significantly different in MSCs cultured in DMEM subjected to TNF-α and IFN-γ 
(MSCs_DMEM TNF+IFN) in comparison with MSCs cultured with no stimuli. 
MSCs_DMEM TNF+IFN 
é%relative ê%relative 
C:N (m/z) C:N (m/z) 
PC(36:1) PC(32:1) 
PC(38:4) PC(32:0) 
SM(34:0) PC(34:1) 
PE(40:6) PC(40:6) 
PS(36:1) PE(38:6) 
LPC(18:0) PS(40:4) 
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2. MSCs cultured in xeno-free media 
The lipid profile of MSCs cultured in xeno-free media (MSCs_XF) was 
obtained and compared with the previous one obtained for MSCs cultured in DMEM 
(MSCs_DMEM). Furthermore, the effects of pro-inflammatory stimuli in MSCs_XF 
were evaluated, in the same manner as what was described previously in this work for 
MSCs_DMEM. 
 
2.1 Effect of culture medium in the profile of fatty acids and phospholipid in MSCs 
MSCs_DMEM and MSCs_XF expressed the same FAs (Figure 11). 
Interestingly no differences were detected in FA profile after pro-inflammatory 
profile. In fact, neither in MSCs_DMEM or MSCs_XF TNF-α and IFN-γ induced 
differences in the levels of FAs (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Fatty acid profile of total lipid extracts from MSCs cultured in DMEM (A) and in 
xeno-free media (B) with no stimuli (Nstim) and MSCs cultured in xeno-free media subjected to 
TNF-α  and IFN-γ  (TNF+IFN). Relative content of the major fatty acids analysed by GC-MS. Values 
are means ± standard deviation of three independent experiments.  
A
 
B
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However, some differences in the levels of specific fatty acids were observed 
between MSCs_DMEM and MSCs_XF (Figure 12, A and B). In fact, both in 
MSCs_XF cultured with no stimuli (MSCs_XF nstim) and MSCs_XF subjected to 
TNF-α and IFN-γ (MSCs_XF TNF+IFN) we observed higher levels of C18:2, along 
with lower levels of C18:0 and C20:4 Δ6 (Figure 12, A and B). In MSCs_XF nstim, 
enhanced expression of C18:1 n9cis was also observed (Figure 12, A). No further 
deviations on the FA profile of MSCs were observed. 
 
Figure 12. Fatty acid profile of total lipid extracts from both MSCs cultured in DMEM and xeno-
free media with no stimuli (A) and subjected to TNF-α  and IFN-γ  (B). Relative content of the 
major fatty acids analysed by GC-MS. Values are means ± standard deviation of three independent 
experiments. ***, significantly different from DMEM (P<0.001). **, significantly different from 
DMEM (P<0.01). *, significantly different from DMEM (P<0.05). 
 51 
MSCs_DMEM and MSCs_XF also expressed the same PL classes (Figure 13, 
A.1 and B.1). In the same manner, MSCs_DMEM and MSCs_XF expressed similar 
amounts of the six identified PL classes when cultured with no stimulus (Figure 14, 
A). However, MSCs_XF TNF+IFN expressed significant lower amounts of SM than 
MSCs_DMEM TNF+IFN (Figure 14, B). 
  
Figure 13. Thin-layer chromatography of total lipid extract obtained from MSCs cultured in 
DMEM with no stimuli (A.1) and MSCs cultured in xeno-free media with no stimuli (B.1). 
Phospholipid standards were also applied: (PC) - Phosphatidylcholine; (PS) - Phosphatidylserine; (PE) 
- Phosphatidylethanolamine; (SM) - Sphingomyelin; (PI) - Phosphatidylinositol; (LPC) - 
Lysophosphatidylcholine.  
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Figure 14. Phospholipid profile of MSCs cultured in DMEM or xeno-free media subjected to no 
stimuli (MSCs nstim) (A) and MSCs subjected to TNF-α  and IFN-γ  (MSCs TNF+IFN) (B). *, 
significantly different from DMEM (P<0.05) 
 
 Besides the fact that both MSCs_DMEM and MSCs_XF expressed the same 
FAs species and the same PL classes, both sets of cells expressed the same PL 
molecular species and similar PL profiles. The molecular profiles of MSCs_XF are 
represented in figures 15 and 16. 
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Figure 15. Percentage of the major phosphatidylcholine (PC) (A), lysoPC (LPC) (B) and 
sphingomyelin (SM) (C) molecular species identified in MSCs cultured in xeno-free media after 
LC-MS and MS/MS analysis. The results were expressed as percentage obtained by dividing the ratio 
between the peak areas of each molecular species and the respective internal standards and the total of 
all ratios. Values are means ± standard deviation of three independent experiments. 
B 
C 
A 
 54 
 
A 
B
 
C
Figure 16. Percentage of the major phosphatidylethanolamine (PE) (A), phosphatidylserine (PS) 
(B) and phosphatidylinositol (PI) (C) molecular species identified in MSCs cultured in xeno-free 
media after LC-MS and MS/MS analysis. The results were expressed as percentage obtained by 
dividing the ratio between the peak areas of each molecular species and the respective internal standards 
and the total of all ratios. Values are means ± standard deviation of three independent experiments. ***, 
significantly different from nstim (P<0.001). 
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As stated above, both MSCs_DMEM and MSCs_XF expressed the same PL 
molecular species and the PL molecular profiles expressed by MSCs_XF are similar 
to the previous ones observed in MSCs_DMEM, except for PE. In PE profile some 
differences were observed between MSCs_DMEM and MSCs_XF (Figure 17). In 
fact, in the case of MSCs_DMEM the most abundant PE specie was PE(40:6) at m/z 
790.3 while PE(38:4) at m/z 766.3, PE(O-38:5) at m/z 750.4 and PE(O-38:6) at m/z 
748.3 were expressed in similar amounts (Figure 17, A). However, in MSCs_XF the 
most abundant PE specie was PE(38:4) at m/z 766.3 and PE(36:1) at m/z 744.3, 
PE(36:2) at m/z 742.3 and PE(O-38:5) at m/z 750.4 were expressed in lower amounts 
(Figure 17, B). 
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Figure 17. Percentage of the major phosphatidylethanolamine (PE) molecular species of MSCs 
cultured in DMEM (A) and of MSCs cultured in xeno-free media identified after LC-MS and 
MS/MS analysis. The results were expressed as percentage obtained by dividing the ratio between the 
peak areas of each molecular species and the respective internal standards and the total of all ratios. 
Values are means ± standard deviation of three independent experiments. ***, significantly different 
from nstim (P<0.001). **, significantly different from nstim (P<0.01). 
 
 
 
 
 
 
B 
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2.2 Effects of TNF-α and IFN-γ in phospholipid profile of MSCs cultured in xeno-free 
media 
 As described previously, TNF-α and IFN-γ induced several differences in the 
levels of specific PL molecular species from MSCs_DMEM. In fact, TNF-α and IFN-
γ led to deviations in the levels of some PC, PE, SM, PS and LPC species (Figures 9 
and 10). 
 Similar to what was observed for MSCs_DMEM, TNF-α and IFN-γ led to no 
deviations in the levels of PI species (Figure 15, C) of MSCs_XF. However, in 
contrast with MSCs_DMEM TNF+IFN, TNF-α and IFN-γ effects in MSCs_XF only 
led to an enhancement on the amount of PS(36:1) at m/z 788.3 (Figure 15, B). Pro-
inflammatory stimuli induced higher expression of PS(36:1) in MSCs_XF, in 
accordance with MSCs_DMEM (Figure 10, B). 
 
  
 
 
 
 
 
 
 
 
IV. Discussion
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Discussion 
This study unveiled the deviations of MSCs lipidome due to pro-inflammatory 
stimuli. MSCs_DMEM lipid profile showed six PL classes: SM, PC, PI, PS, PE and 
LPC (Figure 8, A.1 and A.2). The profile of PC, PI, PS, PE, LPC classes was similar 
to the ones reported in a previous published work (82), but we were able to identify 
the presence of SM in MSCs that was not referenced previously (82). The exposure of 
MSCs_DMEM to TNF-α and IFN-γ caused no significant differences in PLs class 
levels but in contrast some variations were found in specific molecular species within 
all classes, except PI. These variations can be correlated with MSCs’ 
immunomodulatory properties. 
Our study demonstrated that MSCs_DMEM TNF+IFN expressed higher 
levels of PC molecular species with longer FAs chains - PC species (36:1 and 38:4) – 
along with decreased levels of PC molecular species with smaller FAs chains (Figure 
9, A). It was reported that senescence MSCs, which have less immunosuppressive 
capacity, showed the same pattern of deviation regarding PC species with shorter FAs 
chains. However MSCs with weaker immunosuppressive capacity did not enhance 
PC(36:1) levels (82). PC comprises about 50% of total cellular lipids and it is the 
main constituent of eukaryotic cells, where it plays a structural role (92,99,100).  Thus 
it is not expected that PC molecular species contribute directly to the MSCs’ 
immunosuppressive mechanism. Hence we suppose that these changes reflect 
adaptations occurring in MSCs_DMEM when subjected to inflammatory stress. 
Biological membranes have many functions in a cell, which depend on the physical 
state of the bilayer: the bilayer must be fluid in order to assure biological membrane’s 
function (101).  Many factors interfere with membrane fluidity, namely lipid 
composition. In fact, biological membrane with higher levels of long-chain, saturated 
fatty acids is less fluid because those fatty acids are more firmly packed and form 
stronger van der Walls interactions with each other (102,103). MSCs_DMEM 
TNF+IFN expressed higher levels of stearic acid, while the levels of palmitic acid 
were diminished. These results may help to explain the observed changes in PC 
molecular profile of MSCs_DMEM TNF+IFN but also suggests that TNF-α and IFN-
γ stimuli enhanced the activity of elongation of very long chain family member 6 
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(ELOVL6) enzyme. ELOVL6 is the only enzyme capable of elongating C16:0 into 
C18:0 (104). Thereafter, it is probable that MSCs biological membrane becomes less 
fluid when these cells are under pro-inflammatory stimuli. Changes in the membrane 
fluidity can interfere with both the activity of membrane-bond enzymes and the 
function of membrane-bond receptors, affecting signal transduction (105,106). 
 Along with PC species composed of shorter FAs chains, we found that TNF-α 
and IFN-γ led to decreased expression of PC(40:6) in MSCs_DMEM (Figure 9, A) 
assigned by MS/MS as PC 18:0/22:6n-3 (Supplemental Material, Table S1). Because 
higher levels of LPC(18:0) were also observed in MSCs_DMEM TNF+IFN (Figure 9, 
B) and the activity of phospholipase A2 (PLA2) is usually upregulated in 
inflammatory environments, we suppose PLA2 acts upon PC(40:6) releasing 
LPC(18:0) and the fatty acid C22:6n-3. Interestingly, stearoyl 
lysophosphatidylcholine (LPC(18:0)) is one of the main anti-inflammatory LPC 
molecular species, increasing the resistance to LPS-induced mortality and diminishing 
LPS-induced levels of pro-inflammatory cytokines in mice (107). Moreover, 
LPC(18:0) administration also decreased high mobility group box 1 – cytokine 
mediator of inflammation - secretion by macrophages (108). In humans LPC(18:0) 
inhibited LPS-induced tissue factor activity and mRNA expression by human 
monocytes and simultaneously increased monocytes levels of cyclic adenosine 
monophosphate (109). Thereafter we are led to believe LPC(18:0) is a key player in 
the immunomodulator mechanism employed by MSCs. However, while MSCs with 
diminished immunosuppressive capacity showed higher levels of LPC (82), we did 
not observe significant differences in LPC levels as result of TNF-α and IFN-γ stimuli 
(Figure 8, A.2 and B.2). As stated above PLA2 activity upon PCC(40:6) leads to the 
release of C22:6n-3, which is precursor of protectins, resolvin ds and maresins – new 
anti-inflammatory, pro-resolving families of mediators in inflammation (110,111). 
  PE molecular profile is slightly different between MSCs_DMEM TNF+IFN 
and MSCs_DMEM nstim (Figure 10, A). TNF-α and IFN-γ led to enhanced 
expression of PE(40:6) and to declined expression of PE(O-38:6) (Figure 10, A). 
These results are in opposition with the previous reported ones for senescence and 
less active MSCs (82), which indicates that these PE species have important roles in 
the immunosuppressive mechanisms of MSCs. Even though PE acts as a structural 
component in biological membranes, it is also a precursor of other lipids and a 
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subtract for other pathways (92,98). The evidence that levels of some PE molecular 
species are susceptible to TNF-α and IFN-γ is rather interesting because previous 
studies demonstrated PE is capable of bounding hyaluronic acid, inhibiting pro-
inflammatory effects of IFN-γ and lipopolysaccharide in cultured endothelial and 
renal proximal tubular cells, lymphocyte reaction and after mitogen stimulation (112). 
 In opposition to Kilpinen’s report in senescence MSCs (82), we found no 
significant differences in the levels of PS or PI (Figure 8, A.2 and B.2) or in the ratio 
PI/PS between MSCs_DMEM nstim and MSCs_DMEM TNF+IFN. We also did not 
identify differences in the molecular profile of PI between MSCs_DMEM nstim and 
MSCs_DMEM TNF+IFN (Figure 10, C). However, we verified TNF-α and IFN-γ 
caused both enrichment of PS(36:1) and impoverishment of PS(40:4) (Figure 10, B). 
Interestingly PS has been recently highlighted for its immunomodulatory abilities 
(113,114). In a study conducted by Hoffman and colleagues, results showed PS 
inhibited T and B cells responses in spleen and lymph node cells, indicating PS acts 
by regulating inflammation in tissue (113). In a more recent study, investigators came 
to the conclusion that PS interferes with DC cells maturation and T cell activity by 
increasing the production of anti-inflammatory cytokines and simultaneously 
decreasing the production of pro-inflammatory cytokines (114).  
 In the only previous study concerning MSCs’ lipidome, SM molecular profile 
of MSCs was not reported. However, in our study we identified SM as the third most 
abundant PL class. Besides, an increase in the levels of SM(34:0) in MSCs_DMEM 
subjected to TNF-α and IFN-γ was also observed (Figure 9, C). Sphingolipids are one 
of the essential components of lipid membrane and lipid rafts. Therefore, changes in 
sphingolipids’ metabolism can result in lipid membranes and lipid rafts with different 
characteristics, interfering with receptor clustering. Some of sphingolipids’ 
metabolites are bioactive and mediate essential cell functions (115). Actually one of 
those bioactive metabolites – sphingosine-1-phosphate - is capable of down regulate 
mast cells activation. Mast cells secret compounds that trigger allergic responses 
(116). The same metabolite also interferes with T-cell exit from thymus (117) and 
stops macrophages and T cells from enter apoptosis (118,119). Interestingly, despite 
MSCs action over immune system cells, evidences suggest they do not induce 
apoptosis. Moreover some sphingolipids can inhibit T helper cells proliferation (120). 
Curiously, MSCs also act upon T helper cells (60). In a previous work about stem cell 
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homing and mobilization, it was showed that the migration of hematopoietic stem 
progenitor cells is directed by sphingosine-1-phosphate (121). As referred above, 
MSCs are capable of migrating towards inflammation sites (21). 
 From the deviations stated above, the only deviation resultant from TNF-α 
and IFN-γ in MSCs_XF TNF+IFN was assigned as higher levels of PS(36:1). 
Because pro-inflammatory stimuli led to no differences in the levels of PC species, 
we suppose MSCs_XF do not need to make structural adaptations in order to perform 
their mechanisms. However, comparing MSCs_DMEM and MSCs_XF further 
differences were found. In fact, MSCs_XF TNF+IFN express significant lower 
amounts of SM and a slightly different PE molecular profile. Moreover, MSCs_XF 
present enhanced amounts of FA C18:2, along with reduced levels of FAs C18:0 and 
C20:4n-6.  
  
 
 
 
 
 
 
 
 
 
V. Conclusion
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Conclusion 
This study evidences that MSCs phospholipid profile changes when these cells 
are subjected to pro-inflammatory stimulus and these differences are more evident in 
MSCs cultured in a medium supplemented with biological serum. The differences 
were identified only in the level of specific PL molecular species thus suggesting that 
each PL molecular specie could play a role in MSCs’ immunological functionality. 
However, MSCs’ lipidome is far more stable in cells cultured in a synthetic and fully 
controlled medium. In order to fully understand how each one of PL molecular 
species interfere with mechanism of MSCs, further studies are needed. Once levels of 
PS(36:1) were the only ones affected in MSCs from both media by TNF-α and IFN-γ 
and PS is known recognized for its immunomodulatory and anti-inflammatory 
properties abilities, we believe this PL specie is one of the major key players in 
MSCs’ immunosuppressive action. The study of cells’ lipidome is important either to 
understand the MSCs’ immunomodulator mechanism or to be used as a biomarker for 
cells’ functionality. 
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Table S1. Major PC molecular species from MSCs cultured in DMEM with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum 
of the number of carbons and N corresponds to the sum of unsaturation bonds  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+CH3COO]- Fatty Acid Composition m/z (C:N) 
790.17 (32:1) 14:0/18:1 and 14:1/18:0 and 16:0/16:1 
792.35 (32:0) 16:0/16:0 
804.23 (34:1) O-16:0/18:1 
816.15 (34:2) 14:1/20:1 and 16:0/18:2 and 16:1/18:1 
818.19 (34:1) 14:0/20:1 and 16:0/18:1 and 18:0/16:1 and 18:1/16:0 
820.24 (34:0) 16:0/18:0 
830.42 (36:2) Plasmenyl specie 
832.33 (36:1) Plasmenyl specie 
840.14 (36:4) 16:0/20:4 and 18:0/18:4 
842.34 (36:3) 16:0/20:3 
844.25 (36:2) 14:1/22:1 and 18:0/18:2 and 18:1/18:1 
846.22 (36:1) 14:0/22:1 and 16:0/20:1 and 18:0/18:1 
866.14 (38:5) 16:0/22:5 and 18:0/20:5 and 18:1/20:4 and 18:2/20:3 
868.21 (38:4) 18:1/20:3 
870.23 (38:3) ------ 
892.33 (40:6) 18:0/22:6 and 18:1/22:5 and 20:1/20:5 and 20:2/20:4 
894.25 (40:5) 16:0/24:5 and 18:0/22:5 and 18:1/22:4 and 20:0/20:5 and 20:1/20:4 
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Table S2. Major PI molecular species from MSCs cultured in DMEM with no stimuli 
and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of the 
number of carbons and N corresponds to the sum of unsaturations bonds 
[M-H]- Fatty Acid Composition m/z (C:N) 
819.33 (34:2) O-16:0/18:2 and O-16:1/18:1 
821.33 (34:1) Plasmenyl specie 
833.33 (34:2) ------ 
835.42 (34:1) 16:0/18:1 and 16:1/18:0 
849.25 (36:1) Plasmenyl specie 
857.42 (36:4) ------ 
861.42 (36:2) 16:0/20:2 and 16:1/20:1 and 18:0/18:2 and 18:1/18:1 
863.42 (36:1) 16:0/20:1 and 18:0/18:1 
865.25 (36:0) 16:0/20:0 and 18:0/18:0 
867.33 (38:6) O-16:0/22:6 and O-16:1/22:5 
871.33 (38:4) Plasmenyl specie 
883.35 (38:5) 16:0/22:5 and 18:0/20:5 and 18:1/20:4 
885.32 (38:4) 16:0/22:4 and 18:0/20:4 and 18:1/20:3 
887.44 (38:3) 18:0/20:3 and 18:1/20:2 
909.58 (40:6) ------ 
911.25 (40:5) 18:0/22:5 and 18:1/22:4 and 20:1/20:4 and 20:2/20:3 
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Table S3. Major PE molecular species from MSCs cultured in DMEM with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum 
of the number of carbons and N corresponds to the sum of unsaturations bonds 
[M-H]- Fatty Acid Composition m/z (C:N) 
700.33 (34:2)  722.24 (36:5) O-16:0/20:5 and O-16:1/20:4 
742.33 (36:2) 16:0/20:2 and 16:1/20:1 and 18:0/18:2 and 18:1/18:1 
744.33 (36:1) 16:0/20:1 and 18:0/18:1 
746.42 (36:0) 18:0/18:0 
748.33 (38:6) O-16:0/22:6 and O-16:1/22:5 and O-18:1/20:5 and O-18:1/20:4 
750.42 (38:5) O-16:0/22:5 and O-16:1/22:4 and O-18:0/20:5 and O-18:1/20:4 
764.50 (38:5) 16:0/22:5 and 16:1/22:4 and 18:0/22:5 and 18:1/20:4 and 18:2/20:3 
766.25 (38:4) 16:0/22:4 and 16:1/22:3 and 18:0/20:4 and 18:1/20:3 
768.42 (38:3) ------ 
772.33 (38:1) 18:0/20:1 
774.25 (38:0) 18:0/20:0 
774.25 (40:7) O-18:1/22:6 and O-18:2/22:5 
776.50 (40:6) O-18:0/22:6 and O-18:1/22:5 and O-18:2/22:4 
790.33 (40:6) 18:0/22:6 and 18:1/22:5 and 18:2/22:4 and 20:1/20:5 and 20:2/20:4 and 20:3/20:3 
792.35 (40:5) 18:0/22:5 and 18:1/22:4 and 20:0/20:5  and 20:1/20:4 
Table S4. Major PS molecular species from MSCs cultured in DMEM with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum 
of the number of carbons and N corresponds to the sum of unsaturations bonds 
[M-­‐H]-­‐	  
Fatty	  Acid	  Composition	  
m/z	  (C:N)	  
760.29	  (34:1)	   14:0/20:1	  and	  16:0/18:1	  and	  16:1/18:0	  
786.42	  (36:2)	   16:1/20:1	  and	  18:0/18:2	  and	  18:1/18:1	  
788.25	  (36:1)	   16:0/20:1	  and	  16:1/20:0	  and	  18:0/18:1	  
790.42	  (36:0)	   16:0/20:0	  and	  18:0/18:0	  
808.25	  (38:5)	   -­‐-­‐-­‐-­‐-­‐-­‐	  
810.42	  (38:4)	   16:0/22:4	  and	  18:0/20:4	  and	  18:1/20:3	  
812.25	  (38:3)	   18:0/20:3	  
834.20	  (40:6)	   18:0/22:6	  and	  18:1/22:5	  and	  20:1/20:5	  and	  20:2/20:4	  and	  20:3/20:3	  
836.32	  (40:5)	   18:0/22:5	  and	  18:1/22:4	  and	  20:0/20:5	  	  and	  20:1/20:4	  
838.30	  (40:4)	   18:0/22:4	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Table S5. Major LPC molecular species from MSCs cultured in DMEM with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of the 
number of carbons and N corresponds to the sum of unsaturations bonds 
[M+CH3COO]- Fatty Acid Composition m/z (C:N) 
554.02 (16:0) 16:0 
580.42 (18:1) 18:1 
582.25 (18:0) 18:0 
 
Table S6. Major SM molecular species from MSCs cultured in DMEM with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of the 
number of carbons and N corresponds to the sum of unsaturations bonds 
[M+CH3COO]- Fatty Acid Composition m/z (C:N) 
759.27 (34:2) Sphingosine d18:1/16:1 
761.26 (34:1) Sphingosine d18:1/16:0 
763.13 (34:0) Sphinganine d18:0/16:0 
791.08 (36:0) Sphinganine d18:0/18:0 
817.67 (38:1) Sphingosine d18:1/20:0 
819.19 (38:0) Sphinganine d18:0/20:0 
843.33 (40:2) Sphingosine d18:1/22:1 
845.38 (40:1) Sphingosine d18:1/22:0 
871.24 (42:2) Sphingosine d18:1/24:1 
873.34 (42:1) Sphinganine d18:1/24:0 
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Table S7. Major PC molecular species from MSCs cultured in ImmuneSafe® with no stimuli and 
MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of the number of carbons 
and N corresponds to the sum of unsaturations bonds 
[M+CH3COO]- Fatty Acid Composition m/z (C:N) 
790.17 (32:1) 14:0/18:1 and 16:0/16:1 
792.35 (32:0) 16:0/16:0 
804.23 (34:1) O-16:0/18:1 
816.15 (34:2) 14:1/20:1 and 16:0/18:2 and 16:1/18:1 
818.19 (34:1) 14:0/20:1 and 16:0/18:1 and 18:0/16:1 
820.24 (34:0) 16:0/18:0 
830,42 (36:2) Plasmenyl specie 
832,33 (36:1) Plasmenyl specie 
840.14 (36:4) 16:0/20:4 
842.34 (36:3) 16:0/20:3 
844.25 (36:2) 14:1/22:1 and 16:0/20:2 and 16:1/20:1 and 18:0/18:2 and 18:1/18:1 
846.22 (36:1) 16:0/20:1 and 18:0/18:1 
866.14 (38:5) 18:1/20:4 
868.21 (38:4) 18:1/20:3 
870.23 (38:3) ------- 
892.33 (40:6) 18:1/22:5 and 20:2/20:4 
894.25 (40:5) 16:0/24:5 and 18:0/22:5 and 18:1/22:4 and 20:1/20:4 
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Table S8. Major PI molecular species from MSCs cultured in ImmuneSafe® with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of the 
number of carbons and N corresponds to the sum of unsaturations bonds 
[M-H]- Fatty Acid Composition m/z (C:N) 
819.33 (34:2) O-16:0/18:2 and O-16:1/18:1 
821.33 (34:1) Plasmenyl specie 
833.33 (34:2) ------- 
835.42 (34:1) 16:0/18:1 and 16:1/18:0 
849.25 (36:1) Plasmenyl specie 
857.42 (36:4) ------- 
861.42 (36:2) 16:0/20:2 and 16:1/20:1 and 18:0/18:2 and 18:1/18:1 
863.42 (36:1) 16:0/20:1 and 18:0/18:1 
865.25 (36:0) 16:0/20:0 and 18:0/18:0 
867.33 (38:6) O-16:0/22:6 and O-16:1/22:5 
871.33 (38:4) Plasmenyl specie 
883.35 (38:5) 16:0/22:5 and 18:1/20:4 
885.32 (38:4) 16:0/22:4 and 18:0/20:4 and 18:1/20:3 
887.44 (38:3) 18:0/20:3 and 18:1/20:2 
909.58 (40:6) ------- 
911.25 (40:5) 18:0/22:5 and 18:1/22:4 and 20:1/20:4 and 20:2/20:3 
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Table S9. Major PE molecular species from MSCs cultured in ImmuneSafe® with no 
stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of the 
number of carbons and N corresponds to the sum of unsaturations bonds 
[M-H]- Fatty Acid Composition m/z (C:N) 
700.33 (34:2)  722.24 (36:5) O-16:0/20:5 and O-16:1/20:4 
742.33 (36:2) 16:0/20:2 and 16:1/20:1 and 18:0/18:2 and 18:1/18:1 
744.33 (36:1) 16:0/20:1 and 18:0/18:1 
746.42 (36:0) 18:0/18:0 
748.33 (38:6) O-16:0/22:6 and O-16:1/22:5 and O-18:1/20:5 and O-18:1/20:4 
750.42 (38:5) O-16:0/22:5 and O-16:1/22:4 and O-18:0/20:5 and O-18:1/20:4 and O-18:2/20:3 
764.50 (38:5) 16:0/22:5 and 16:1/22:4 and 18:0/22:5 and 18:1/20:4 and 18:2/20:3 
766.25 (38:4) 16:0/22:4 and 16:1/22:3 and 18:0/20:4 and 18:1/20:3 
768.42 (38:3) ------- 
772.33 (38:1) 18:0/20:1 
774.25 (38:0) 18:0/20:0 
774.25 (40:7) O-18:1/22:6 and O-18:2/22:5 
776.50 (40:6) O-18:0/22:6 and O-18:1/22:5 and O-18:2/22:4 
790.33 (40:6) 18:0/22:6 and 18:1/22:5 and 18:2/22:4 and 20:1/20:5 and 20:2/20:4 and 20:3/20:3 
792.35 (40:5) 16:1/24:4 and 18:0/22:5 and 18:1/22:4 and 18:2/22:3 and 20:0/20:5 and 20:1/20:4 and 20:2/20:3 
 
 
Table S10. Major PS molecular species from MSCs cultured in ImmuneSafe® with 
no stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of 
the number of carbons and N corresponds to the sum of unsaturations bonds 
[M-H]- Fatty Acid Composition m/z (C:N) 
760.29 (34:1) 16:0/18:1 and 16:1/18:0 
786.42 (36:2) 18:0/18:2 and 18:1/18:1 
788.25 (36:1) 16:0/20:1 and 16:1/20:0 and 18:0/18:1 
790.42 (36:0) 16:0/20:0 and 18:0/18:0 
808.25 (38:5) ------- 
810.42 (38:4) 16:0/22:4 and 18:0/20:4 and 18:1/20:3 and 18:2/20:2 
812.25 (38:3) 16:1/22:2 and 18:0/20:3 and 18:1/20:2 
834.20 (40:6) 18:0/22:6 and 18:1/22:5 and 20:1/20:5 and 20:2/20:4 and 20:3/20:3 
836.32 (40:5) 18:0/22:5 and 18:1/22:4 and 20:1/20:4 
838.30 (40:4) 18:0/22:4 and 18:4/22:0 and 18:1/22:3 and 20:0/20:4 and 20:1/20:3 
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Table S11. Major LPC molecular species from MSCs cultured in ImmuneSafe® with 
no stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of 
the number of carbons and N corresponds to the sum of unsaturations bonds 
[M+CH3COO]- Fatty Acid Composition m/z (C:N) 
554.02 (16:0) 16:0 
580.42 (18:1) 18:1 
582.25 (18:0) 18:0 
 
Table S12. Major SM molecular species from MSCs cultured in ImmuneSafe® with 
no stimuli and MSCs subjected to TNF-α and IFN-γ. (C:N) – C indicates the sum of 
the number of carbons and N corresponds to the sum of unsaturations bonds 
[M+CH3COO]- Fatty Acid Composition m/z (C:N) 
759.27 (34:2) Sphingosine d18:1/16:1 
761.26 (34:1) Sphingosine d18:1/16:0 
763.13 (34:0) Sphinganine d18:0/16:0 
791.08 (36:0) Sphinganine d18:0/18:0 
817.67 (38:1) Sphingosine d18:1/20:0 
819.19 (38:0) Sphinganine d18:0/20:0 
843.33 (40:2) Sphingosine d18:1/22:1 
845.38 (40:1) Sphingosine d18:1/22:0 
871.24 (42:2) Sphingosine d18:1/24:1 
873.34 (42:1) Sphinganine d18:1/24:0 
 
